Discovery of Novel Adenosine Receptor Agonists that Exhibit Subtype Selectivity

Anthony Knight,^{†,#} Jennifer L. Hemmings,^{‡,#} Ian Winfield,^{¶,⊥} Michele Leuenberger,[‡] Eugenia Frattini,[⊥]
Bruno G. Frenguelli,[§] Simon J. Dowell,^{||} Martin Lochner,^{*,‡} and Graham Ladds^{*,⊥}

[†]Systems Biology Doctoral Training Centre, University of Warwick, Coventry, CV4 7AL, UK.

[‡]Department of Chemistry and Biochemistry, University of Bern, 3012 Bern, Switzerland.

[¶]Division of Biomedical Cell Biology, Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK.

[§]School of Life Sciences, University of Warwick, Coventry CV4 7AL, UK.

^{||}Department of Platform Technology and Science, GlaxoSmithKline, Hertfordshire, SG1 2NY, UK.

[⊥]Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, UK.

Running Title: Investigating adenosine receptor selectivity of *N*⁶-modified agonists.

Keywords: GPCRs; adenosine receptor; selectivity; G proteins; yeast.

Abstract

A series of N^6 -bicyclic and N^6 -(2-hydroxy)cyclopentyl derivatives of adenosine were synthesized as novel A_1R agonists and their A_1R/A_2R selectivity assessed using a simple yeast screening platform. We observed that the most selective, high potency ligands were achieved through N^6 -adamantyl substitution in combination with 5'- N -ethylcarboxamido or 5'-hydroxymethyl groups. In addition, we determined that 5'-(2-fluoro)thiophenyl derivatives all failed to generate a signaling response despite showing an interaction with the A_1R . Some selected compounds were also tested on A_1R and A_3R in mammalian cells revealing that four of them are entirely A_1R -selective agonists. By using *in silico* homology modeling and ligand docking, we provide insight into their mechanisms of recognition and activation of the A_1R . We believe that given the broad tissue distribution, but contrasting signaling profiles, of adenosine receptor subtypes these compounds might have therapeutic potential.

Introduction

Adenosine receptors (ARs) belong to the family of G protein-coupled receptors (GPCRs) and exist as four different subtypes, A₁, A_{2A}, A_{2B} and A₃. All subtypes respond to the purinergic nucleoside adenosine, but they have a wide and varying tissue distribution. Many ARs have been linked to cardiovascular, respiratory and inflammatory disorders.¹ Furthermore, in the central nervous system they have been implicated in acute pathological conditions such as epilepsy, hypoxia and ischemia,^{2,3} and chronic neurodegenerative disorders, such as Parkinson's, Alzheimer's and Huntington's diseases.⁴ In human cells, the A₁R and A₃R predominantly couple to the Gα_i family of G proteins, inhibiting the production of cAMP, while the A₂R subtypes couple to the Gα_s subunit, stimulating adenylate cyclase to elevate cAMP levels. Given their common ligands, diametrically opposed effects and overlapping tissue distribution the ARs have been the focus of extensive research to discover subtype selective ligands. However, limitations of mammalian systems can hinder the testing and development of these compounds. For instance, the A₁R can signal through the Gα_{i1}, Gα_{i3} and Gα_o⁵ but it is currently difficult to differentiate between these effectors in an *in vivo* mammalian cell-based assay.

Most of the known AR agonists are based on the adenosine scaffold and receptor subtype selectivity can be achieved by substituting the purine ring of the nucleoside at positions C-2 and/or N⁶ with appropriate functional groups. For instance, substitution of the N⁶-position with bulky cycloalkyl- and bicycloalkyl groups has resulted in A₁R-selective agonists.⁶⁻¹⁰ Introduction of a wide range of N⁶-substituents is conveniently achieved by nucleophilic aromatic substitution of the corresponding 6-chloro purine precursor with primary or secondary amines. The ribose moiety, in particular at the C-2', C-3' and C-5' positions, have also been the subject of many modifications which can influence A₁R affinity, selectivity and efficacy.^{8,11,12} 5'-Carboxamido adenosine derivatives, such as the prototypical AR agonist 5'-N-ethylcarboxamidoadenosine (NECA), among many other examples, are known to be potent activators. More bulky groups, such as substituted 5'-thioaryl and 5'-oxoaryl moieties have also been explored and these studies have provided novel A₁R-selective and potent agonists.^{13,14} In light of this, we designed a

series of adenosine analogues that feature different cyclic and bicyclic substituents at the N^6 of the purine ring and various functional groups at the C-5' of the ribose in order to assess the effect of these modifications on AR activity and subtype selectivity.

We¹⁵⁻²⁰ and others^{5,21-23} have previously described the use of modified *Saccharomyces cerevisiae* strains containing chimeric (yeast-human) G protein alpha subunits to functionally couple heterologously expressed GPCRs. Specifically, the chimeric G proteins enable mammalian GPCRs to functionally couple to the yeast-mating pathway. This pathway includes a reporter (*FUS1-lacZ*) gene providing a quantitative assay for GPCR activation.¹⁶ The yeast platform provides a simple, affordable and robust assay with which to identify novel GPCR ligands and their interactions with a single effector.^{17,24,25} This system has also been established to study A_1R , $A_{2A}R$ and $A_{2B}R$ in a number of G protein backgrounds,^{5,18,21-23} although evidence of functional couplings of the A_3R has not been reported.

In this study we exploit the yeast system to characterize novel synthetic adenosine derivatives for their agonist activity against the A_1R , $A_{2A}R$ and $A_{2B}R$. We explored subtype selectivity further at the A_1R and A_3R in mammalian CHO-K1 cells for the compounds that were active against the A_1R in the yeast screen. Moreover, we use homology modeling and docking to gain insight into the binding of our agonists at the A_1R . Our yeast-based screen and mammalian cell assays have identified novel adenosine nucleosides exhibiting interesting A_1R selective profiles. Hence, they constitute valuable tool compounds for cellular studies and might have therapeutic potential.

Results and Discussion

Chemistry

Known compounds **5**,²⁶ **6**²⁷ and **7**²⁸ have previously been shown to be selective for the A_1R with respect to their binding affinity. These analogues were prepared for assessment using our yeast-based assay. Bulky bicyclic groups have been highlighted as beneficial for A_1R selectivity,⁷⁻¹⁰ so we also prepared novel

compound **9**. Intermediate **2** was required for efficient generation of the analogues (Scheme 1). This was synthesized according to the procedure adopted by Kotra *et al.*,²⁹ with minor experimental modifications.

Scheme 1. Synthesis of Adenosine Derivatives^a

^a Reagents and conditions: (a) procedures according to reference 29; (b) R-NH₂, Et₃N or DIPEA, EtOH, reflux, 18 h to 5 days (for specific conditions and yields see *Experimental Section*); (c) K₂CO₃, MeOH, rt, 3 h, 99%; (d) **4**, Pd(OH)₂, cyclohexene, ethanol, reflux, 18 h, 99%; (e) (1*R*,3*r*,5*S*)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine, DIPEA, EtOH, reflux, 18 h, 54%; (f) K₂CO₃, MeOH, rt, 3 h, 99%.

Aromatic substitution of the *N*⁶-chloro group with 1-adamantylamine or (1*R*,2*R*)-1-amino-2-benzyloxycyclopentane was carried out in the presence of triethylamine or Hünig's base. This resulted in partial deacetylation to give the monoacetylated products (**3** and **4**), which could be attributed to the use of excess base. The presence of the acetyl on the primary alcohol was confirmed using ¹H NMR and was then removed using potassium carbonate in methanol to give **5** and **6** in quantitative yield. The choice of base did not appear to have an effect on the reaction. Attempts to directly remove the benzyl group from **6** using hydrogenolysis returned unreacted starting material. However, treatment of monoprotected **4** with Pearlman's catalyst and cyclohexene afforded **7**. Interestingly, aromatic substitution with (1*R*,3*r*,5*S*)-9-

methyl-9-azabicyclo[3.3.1]nonan-3-amine (granatanamine) using less base did not result in deacetylation and afforded the expected product **8**. Deprotection was again carried out with potassium carbonate and methanol. Granatanamine was prepared according to a procedure previously developed in our group.³⁰

Despite the widespread use of 5'-*N*-ethylcarboxamidoadenosine (NECA) as an A₁R agonist we found that the analogous cyclopentyl (**21**) and adamantyl (**16**) congeners were novel compounds and to the best of our knowledge untested at the A₁R. This is possibly a consequence of the non-selective nature of NECA at the AR subtypes.³¹ In this case intermediate **10** was required to allow generation of novel analogues (Scheme 2).

Scheme 2. Synthesis of Novel NECA Derivatives^a

^a Reagents and conditions: (a) procedures according to reference 32; (b) R-NH₂, Et₃N or DIPEA, EtOH, reflux, 18 h to 5 days (for specific conditions and yields see *Experimental Section*); (c) acetic acid, water, 80 °C, 18 h, 99%; (d) *tert*-butyl-9-azabicyclo[3.3.1]nonan-3-yl carbamate (**22**), DIPEA, EtOH, reflux, 18

h, 85%; (e) acetic acid, water, 80 °C, 18 h, 99%; (f) formic acid, formaldehyde (37% aq.), reflux, 18 h, 63%; (g) **20**, Pd(OH)₂, cyclohexene, ethanol, reflux, 18 h, 99%.

The amide building block **10** was prepared from **1** as previously reported by Middleton *et al.*³² Displacement of the chloride in **10** with the appropriate amine in the presence of either Hünig's base or triethylamine gave intermediates **11–15**. This reaction proceeded with ease in refluxing ethanol overnight in the case of **13–15**, however all 1-adamantyl analogues required one week at reflux to generate sufficient quantities of desired compounds. Interestingly, the 2-adamantylamine reaction was complete within one day. Acetonide deprotection was achieved by heating overnight in acetic acid and water to generate **16–20** with quantitative yields observed. Removal of the benzyl protecting group from **20** with palladium hydroxide and cyclohexene to generate **21** proceeded in quantitative yield. We decided to prepare analogues **24** and **25** with the alternative bicyclic architecture to allow us to probe the necessity for a secondary amine at the adenine N⁶ position. Chloride **10** was reacted with granatyl secondary amine **22**, which was prepared according to a literature protocol.³³ Like the adamantyl analogues, this reaction was very slow and required reflux for one week to generate sufficient quantities of product to give **23**. Concomitant deprotection of the acetonide and Boc group occurred on treatment with acetic acid and water to give **24**. The dimethylamine **25** was then prepared using formic acid and formaldehyde.

Given the prior studies on CVT-3619 (**37**) showing that it is a specific partial agonist at the A₁R¹⁴ we prepared this compound for assessment using our yeast-based assay and planned to prepare new analogues with the 2-fluorothiophenol group at the C-5' position of the ribose ring. In alignment with our strategy for adenosine and NECA analogues we required chloride **27**, which would allow efficient generation of analogues with various cyclic groups at the N⁶ position of the adenine (Scheme 3). Primary chloride **27** was prepared from protected **26** using Appel conditions according to the previously reported procedure.³⁴ Treatment with 2-fluorothiophenol and sodium hydride gave **28** in 48% yield and subsequent chlorination with our previously adopted conditions of thionyl chloride and DMF gave **29** in 88% yield.

Introduction of the cyclic component was accomplished by reacting with the appropriate primary amine in the presence of DIPEA or triethylamine to give **30–33**. Again, preparation of the adamantyl analogue required one week at reflux to obtain the product in sufficient yield. Initial attempts to directly remove the benzyl protecting group from **32** with palladium hydroxide and cyclohexene to generate **37** were unsuccessful. However, 6-chloropurine **29** reacted readily with (1*R*,2*R*)-2-aminocyclopentanol to generate the desired product directly. Acetonide deprotection with acetic acid and water at reflux generated final compounds **34–37** in excellent yields.

Scheme 3. Synthesis of CVT-3619 and New Derivatives^a

^a Reagents and conditions: (a) CCl₄, PPh₃, DMF, rt, 18 h, 53%; (b) 2-fluorothiophenol, NaH, DMF, 0 °C to rt, 3 h, then chloride **27**, DMF, rt, 18 h, 48%; (c) SOCl₂, DMF, DCM, 50 °C, 5 h, 88%; (d) R-NH₂, Et₃N or DIPEA, EtOH, reflux, 18 h to 3 days (for specific conditions and yields see *Experimental Section*); (e) acetic acid, water, 80 °C, 18 h, 99%.

Biological Activity

We expressed all four AR subtypes, under the control of the constitutive *GAPDH* promoter, in a panel of transplant yeast strains engineered to contain chimeric $G\alpha$ -subunits in which the 5 C-terminal amino acids of Gpa1p have been replaced with those mammalian $G\alpha_q$, $G\alpha_{12}$, $G\alpha_o$, $G\alpha_{i1/2}$, $G\alpha_{i3}$, $G\alpha_z$ and $G\alpha_s$. Efficient trafficking of the A_1R , $A_{2A}R$ and $A_{2B}R$ to the cell surface in yeast cells was confirmed using modified receptors engineered to contain a GFP fluorophore at the C-terminus (Figure 1A). NECA is a non-subtype selective AR agonist and was used to determine through which $G\alpha$ -subunits each receptor signaled. Yeast cells were exposed to 100 μ M NECA for 16 hours and reporter gene activity (as measured through β -galactosidase production) was determined (Figure 1B-D).

Figure 1. NECA-activated yeast-mating pathway via specific AR/ $G\alpha$ protein chimeras. (A) A C-terminal GFP tag was engineered onto the A_1R , $A_{2A}R$ and $A_{2B}R$ and expression at the plasma membrane was confirmed using fluorescence microscopy. Scale bar = 5 μ m. (B-D) Yeast strains expressing the human (B)

A₁R, (C) A_{2A}R (D) A_{2B}R were stimulated with 0 or 100 μ M NECA for 16 h and assayed for the activation of the *FUS1-lacZ* reporter gene as previously described.^{15-17,19} β -galactosidase units (mU) are expressed as the ratio of *o*-nitrophenol product to cell density (determined colorimetrically; see *Experimental Section*). Data are the mean of 5 independent experiments $\pm$ SEM. Data were determined as significantly different from the non-ligand response using Student's *t*-test where *, $p < 0.05$, **, $p < 0.01$, ***, $p < 0.001$.

Consistent with previous reports^{5,22} the A₁R generated significant ($p < 0.05$) responses in strains expressing G protein chimeras corresponding to G α_o , G α_{i1} and G α_{i3} (Figure 1B). In addition, we also report for the first time, functional coupling of the A₁R signaling through the GPA1/G α_z transplant. Signaling was not observed via GPA1/G α_q , GPA1/G α_{12} or GPA1/G α_s or the unmodified Gpa1p ($n \geq 16$ isolates screened for functionality). Further, we observed that the A_{2A}R and A_{2B}R (Figure 1C and 1D) signaled through both GPA1/G α_s and GPA1/G α_{i1} but we failed to identify any functional coupling for the A₃R in our panel of strains (Supplementary Figure S1). Moreover, we report that, the A_{2A}R displayed significantly elevated levels of ligand-independent signaling which is consistent with previous observations in yeast.¹⁸ While we have observed that these GPCRs can couple to a number of different Gpa1p chimeras, we have chosen to focus on the ones that are widely reported to be the most physiologically relevant in mammalian cells. Consequently, the A₁R-GPA1/G α_{i1} , A_{2A}R-GPA1/G α_s and A_{2B}R-GPA1/G α_s strains were chosen for further compound characterization.

Subtype Selectivity of Adenosine Derivatives in Yeast. Having identified yeast strains that functionally express the A₁R, A_{2A}R and A_{2B}R, we sought to validate their pharmacology in response to a range of agonists. Dose-response curves were determined for NECA, adenosine, 2-chloro-*N*⁶-cyclopentyladenosine (CCPA) and CGS-21680 (Figure 2) using the yeast reporter assay. Sigmoidal dose-response curves were observed allowing the maximum response (E_{max}) and potency (pEC₅₀) to be determined (Table 1). NECA, adenosine and CCPA are full agonists at the A₁R (E_{max} compared with NECA by one-way ANOVA, $p > 0.05$) but have differing potencies (Table 1). This generates a rank order of

potency for the ligands of CCPA > NECA > adenosine. CGS-21680 had a much lower potency than the other ligands ($pEC_{50} = 3.2 \pm 0.1$) and failed to reach a maximal response. While the overall potency values are lower than observed in mammalian cells, the rank order of the ligands is conserved between yeast and mammalian systems.³⁵ Application of the operational model of pharmacological agonism³⁶ enabled calculation of the ligand binding affinity (pK_A) and efficacy (τ) (Table 2). In comparison to NECA, both adenosine and CCPA have a greater pK_A and a reduced τ .

Figure 2. AR agonists display receptor subtype selectivity. Dose-response curves for various AR agonists were generated from yeast strains expressing (A) A₁R, (B) A_{2A}R and (C) A_{2B}R following stimulation for 16 h with (●) NECA, (○) adenosine, (■) CCPA or (□) CGS-21680. Activation of the reporter gene was calculated and is expressed as the percentage of the maximum response achieved when cells were stimulated with the reference agonist NECA. (D-F) Receptor selectivity was calculated as the change in log (τ/K_A), relative to NECA, for the data in A-C. Data were determined as statistically different (**, $p < 0.01$, ***, $p < 0.001$) from NECA, using a one-way ANOVA with Bonferroni's post-test. All data are mean of 5-8 independent experiments $\pm$ SEM.

Table 1. Potency (pEC₅₀) and Maximal Response (E_{max}) of Reference Compounds and Synthetic

Adenosine Derivatives at A₁R, A_{2A}R and A_{2B}R as measured in Yeast^a

Compd	R ₁	R ₂	A ₁ R		A _{2A} R		A _{2B} R	
			pEC ₅₀ ^b	E _{max} ^c	pEC ₅₀ ^b	E _{max} ^c	pEC ₅₀ ^b	E _{max} ^c
NECA	-CONHEt	-NH ₂	6.0 ± 0.1	100 ± 2.4	6.47 ± 0.2	100 ± 2.0*	4.83 ± 0.1	100 ± 3.8
Adenosine	-CH ₂ OH	-NH ₂	5.6 ± 0.1*	91.4 ± 2.8	5.24 ± 0.8	65.9 ± 1.7**	4.29 ± 0.1	70.4 ± 2.9**
CCPA	-	-	6.7 ± 0.1***	80.9 ± 2.2	5.00 ± 0.2	74.7 ± 4.9	4.14 ± 0.1	30.6 ± 2.0***
CGS-21680	-	-	3.2 ± 0.1***	91.3 ± 14.1	4.70 ± 0.1*	121.7 ± 4.1	2.20 ± 0.6***	59.1 ± 2.8***
5	-CH ₂ OH		4.8 ± 0.1***	98.5 ± 4.1	N.R. ^d		N.R.	
6	-CH ₂ OH		5.8 ± 0.1	89.8 ± 1.8	N.R.		N.R.	
7	-CH ₂ OH		6.2 ± 0.1	83.7 ± 4.4	N.R.		N.R.	
9	-CH ₂ OH		N.D. ^e		N.R.		N.R.	
16	-CONHEt		5.4 ± 0.0***	104.4 ± 1.3	N.R.		N.R.	
17	-CONHEt		4.0 ± 0.1***	100 ± 23.7	N.R.		N.R.	
18	-CONHEt		4.8 ± 0.0***	107.7 ± 3.0	N.R.		N.R.	
19	-CONHEt		N.D.		N.R.		N.R.	
20	-CONHEt		6.0 ± 0.1	99.3 ± 0.3	4.8 ± 0.3*	115.0 ± 13.0	3.9 ± 0.3	32.2 ± 11.4***
21	-CONHEt		6.5 ± 0.1**	99.0 ± 2.8	5.24 ± 0.3	77.7 ± 4.6	3.48 ± 0.3*	49.2 ± 0.4***
24	-CONHEt		N.R.		N.R.		N.R.	
25	-CONHEt		N.R.		N.R.		N.R.	

34			N.R.	N.D.	N.R.
35			N.R.	N.R.	N.R.
36			N.R.	N.R.	N.R.
37			N.R.	N.R.	N.R.

Values are the mean $\pm$ SEM from 5-8 independent repeats.

^aA₁R and A₂R receptors in GPA1/G α_{i1} and GPA1/G α_s yeast transplants, respectively.

^bNegative logarithm of the agonist concentration required to induce a half-maximal response.

^cThe maximal response to a ligand expressed as a percentage of that obtained for NECA.

^dN.R., no response.

^eN.D., not determined. Full dose-response curve was not feasible.

Statistical significance compared to NECA (*, $p < 0.05$, **, $p < 0.01$, ***, $p < 0.001$) was determined by one-way ANOVA with Dunnett's post-test.

Table 2. Ligand Affinity (pK_A) and Efficacy (log τ) of Reference Compounds and Synthetic Adenosine Derivatives at A₁R, A_{2A}R and A_{2B}R expressed in Yeast^a

Compd	A ₁ R		A _{2A} R		A _{2B} R	
	pK _A ^b	log τ ^c	pK _A ^b	log τ ^c	pK _A ^b	log τ ^c
NECA	4.4 ± 0.1	1.5 ± 0.1	5.9 ± 0.2	0.5 ± 0.1	4.2 ± 0.1	0.6 ± 0.1
Adenosine	4.6 ± 0.2	0.9 ± 0.1	5.6 ± 0.2	0.0 ± 0.3	3.8 ± 0.1	0.3 ± 0.1
CCPA	6.1 ± 0.1	0.6 ± 0.1	4.7 ± 0.3	-0.1 ± 0.1	4.4 ± 0.1	3.5 ± 0.1***
CGS-21680	2.1 ± 0.9*	1.1 ± 0.9	4.9 ± 0.1	-0.3 ± 0.0	3.4 ± 0.1	-0.2 ± 0.0
5	3.0 ± 1.1	1.8 ± 1.1	N.R. ^d		N.R.	
6	4.9 ± 0.1	0.5 ± 0.1	N.R.		N.R.	
7	5.5 ± 0.1	0.7 ± 0.1	N.R.		N.R.	
9	N.R.		N.R.		N.R.	
16	4.2 ± 0.3	1.2 ± 0.3	N.R.		N.R.	
17	3.5 ± 0.1	1.0 ± 0.1	N.R.		N.R.	
18	2.4 ± 0.1*	2.4 ± 0.0	N.R.		N.R.	
19	N.R.		N.R.		N.R.	
20	4.3 ± 0.5	1.6 ± 0.5	3.9 ± 0.7**	0.5 ± 0.5	3.5 ± 0.6	0.1 ± 0.5
21	4.8 ± 0.5	1.6 ± 0.5	4.6 ± 0.4	0.3 ± 0.1	4.2 ± 0.1	-0.2 ± 0.1
24	N.R.		N.R.		N.R.	
25	N.R.		N.R.		N.R.	
34	N.R.		N.D. ^e		N.R.	
35	N.R.		N.R.		N.R.	
36	N.R.		N.R.		N.R.	
37	N.R.		N.R.		N.R.	

Values are the mean ± SEM from 5-8 independent repeats.

^aA₁R and A₂R in GPA1/Gα_{i1} and GPA1/Gα_s yeast transplants, respectively.

^bNegative logarithm of the relative equilibrium disassociation constant for each compound generated through use of the operational model of agonism.³⁶

^cThe coupling efficiency parameter (τ), generated by comparison to NECA.

^dN.R., no response.

^eN.D., not determined. Full dose-response curve was not feasible.

Statistical significance compared to NECA (*, $p < 0.05$, **, $p < 0.01$, ***, $p < 0.001$) was determined by one-way ANOVA with Dunnett's post-test.

We next sought to investigate the pharmacological properties of the A_{2A}R expressed in our GPA1/Gα_s expressing strains. Both CGS-21680 and NECA displayed strong agonism at the A_{2A}R, while adenosine and CCPA showed weak partial agonism (Figure 2B). Further, all ligands assayed display weak potency at the A_{2B}R, (rank ligand potencies, NECA > adenosine = CCPA >> CGS-21680) with CGS-21680 failing to generate a maximal response at the ligand concentrations assayed. Thus, in our strains, CGS-21680 would appear to be largely A_{2A}R selective and this is consistent with mammalian cell affinity data.^{31,35}

We next sought to compare the selectivity/preference that ligands may possess for each of the ARs. Expression of the ARs in yeast generates a clean, robust assay, with no competing signaling machinery, so enabling the proportioning of receptor responses to individual signaling pathways. We have previously used the methods developed by Figuero *et al.*³⁷ to quantify ligand bias for receptors expressed in yeast.^{19,20} Here we report the adaptation of the equimolar method of comparison³⁷ to quantify a ligands selectivity for a given receptor (see *Experimental Section* for more details). Since NECA is a full agonist for all three ARs expressed in yeast, it can be used as a reference ligand. By calculating the change in log (τ/K_A), for an agonist relative to NECA, for each AR subtype we have generated a quantitative means of comparing receptor selectivity for all our agonists (Figure 2D-F). Adenosine and CCPA are A₁R-selective but also preferentially activate A_{2B}R over A_{2A}R. In contrast, CGS-21680 is A₂R subtype-selective with an overall preference for the A_{2A}R.

Bulkier N⁶-adamantyl agonists have previously been shown to be A₁R selective with respect to binding affinity at rat receptors.²⁶ Therefore we extended our studies to include novel AR agonists containing an adamantyl group. **5**, **16-18** were derived from adenosine and NECA respectively (Schemes 1-2). These compounds appeared to be A₁R selective full agonists compared with NECA, with no significant response detected at the A_{2A}R and A_{2B}R ($p > 0.05$) (Figure 3A-C). However, **5**, **16-18** displayed reduced potency to the A₁R compared to their precursors and cyclopentyl variants (Table 1). Furthermore, pK_A values suggested this might be a consequence of reduced ligand binding affinities (Table 2).

A₁R agonists derived from adenosine with substituted cyclopentyl groups at the adenine N⁶ position have been reported previously (e.g. GR79236, *N*-[(1*S*,2*S*)-(2-hydroxy)cyclopentyl]adenosine).³⁸ We found that *N*⁶-cyclopentyl derivatives **6**, **7**, **20** and **21** mainly signal through the A₁R, but for the latter two compounds minimal responses were also detected at A_{2A}R and A_{2B}R (Table 1, Figure 4).

Figure 3. *N*⁶-adamantyl derivatives selectivity at the human A₁R. Yeast strains expressing (A) A₁R, (B) A_{2A}R and (C) A_{2B}R were stimulated with *N*⁶-adamantyl derivatives (▼) **5**, (▽) **16**, (◇) **17**, (●) **18** and (◆) **34** for 16 h and reporter gene activity determined. Data are expressed as the percentage of the maximum response achieved when cells were stimulated with the reference agonist NECA (grey dotted line). All data are mean of 5-8 independent experiments ± SEM.

Adenosine derivative **6** was highly A₁R selective but failed to produce a maximal signal. In a patent in 2011²⁷ **6** was described as an A₁R-selective agonist for reducing elevated intraocular pressure in the treatment of glaucoma or ocular hypertension and this compound was assessed for selectivity with respect to binding affinity (*K_i*) at human subtypes A₁, A_{2A} and A₃.²⁷ In accordance with our results it was shown, using a radioligand displacement assay, that **6** binds with greater than 250-fold affinity at the A₁ over the A_{2A} subtype. In the yeast-based assays the novel NECA analogues **20** and **21** have equal or higher potency, respectively, than the parent compound NECA at the A₁R. However, in contrast to the *N*⁶-cyclopentyl adenosine derivatives **6** and **7**, *N*⁶-cyclopentyl NECA derivatives **20** and **21** are non-selective and signal

through the A₁R, A_{2A}R and A_{2B}R (Table 1). Calculation of selectivity factors confirm that **21** preferentially signals A₁R > A_{2B}R > A_{2A}R.

As described above, the *N*⁶-adamantyl derivatives only induced a detectable response in A₁R-expressing yeast strains, suggesting that bulky *N*⁶-substituents promote total A₁R/A₂R selectivity. To explore this further we created a series of ligands containing an *N*⁶-azabicyclo (granatane) moiety. Compounds **9**, **19**, **24** and **25** were screened for activity; however, no significant response was detected for these compounds via the A₁R, A_{2A}R or A_{2B}R (*p* > 0.05, one-way ANOVA). Some minimal response was observed for **9** and **19** at very high concentration (100 μM) but it was not feasible to generate full dose-response curves (Table 1).

Figure 4. *N*⁶-(2-Hydroxy)cyclopentyl derivatives of both adenosine and NECA display bias towards the A₁ receptor. Yeast strains expressing the A₁R (A and D), the A_{2A}R (B and E) and the A_{2B}R (C and F) were stimulated for 16 h with *N*⁶-(2-hydroxy)cyclopentyl derivatives (▲) **7** and (△) **21** or *N*⁶-(2-

benzyloxy)cyclopentyl derivatives ($\square$) **6**, ($\blacksquare$) **20** and ($\circ$) **36** and assayed for activation of the *FUS1*> *lacZ* reporter gene. Data are expressed as the percentage of the maximum response achieved when cells were stimulated with the reference agonist NECA (grey dotted line). Data are mean of at least five independent experiments $\pm$ SEM.

Replacement of the 5'-ethyl carboxamide or 5'-hydroxy group with a 2-fluorothiophenyl moiety, as in adenosine analogues **34-37**, resulted in compounds that failed to produce any detectable response in the A₁R, A_{2A}R and A_{2B}R strains (Table 1). In fact, **34** was only able to activate the A_{2A}R but at concentrations of greater than 100 μ M. These results were somewhat surprising since the *N*⁶-hydroxycyclopentyl congener **37** (CVT-3619, later named GS 9667) has previously been described as a selective, partial agonist of the A₁R, with reported *K*_i values of 113 nM and 1.1 μ M when challenged with the antagonist [³H]CPX, binding in hA₁R-expressing DDT₁MF-2 and CHO cells, respectively.¹⁴ To determine if the lack of functional activity for **34**, **36** and **37** in our yeast assays resulted from the compounds failing to cross the membrane, we performed a competition assay between **34**, **36** and **37** and either NECA, adenosine or CCPA at the A₁R (Supplementary Figure S2).

In line with the previously reported data,¹⁴ we confirmed **37** does appear to compete with all three ligands at the A₁R ($pA_2 = 5.3 \pm 0.4$). Interestingly, despite the fact that **37** interacts with the A₁R, in our experimental system, it appears unable to induce a measurable response. It is worth noting that, A₁R agonist activity of **37** (CVT-3619) was previously demonstrated in rat adipocytes where it reduced cAMP content and consequently lipolysis¹⁴ although it is entirely possible that the observed response in these cell lines resulted from “off-target activation” of other receptors. Despite entering clinical trials where it was evaluated for its efficacy to lower lipids and thus improve glycemia, CVT-3619 (**37**) showed inadequate pharmacokinetics and it was discontinued.³⁹ Furthermore, some recent studies suggest that the A₁R may not play a significant role in hepatic regulation of lipid metabolism.⁴⁰ Similar to **37**, close analog **36** also

acted as a competitive antagonist at A₁R ($pA_2 = 6.4 \pm 0.2$, Supplementary Figure S2) but **34** did not appear to bind to the A₁R at all.

Determining A₁R versus A₃R Selectivity in Mammalian Cells. Traditionally, many compounds that display selectivity for the A₁R compared to the A₂Rs frequently also display activity to the A₃R. However, as described previously, we were unable to obtain functional coupling of the A₃R to the yeast pheromone-response pathway (Supplementary Figure S1). Thus, to provide a complete characterization of the A₁R-selective compounds isolated in the yeast screen, we utilized mammalian CHO-K1 cells transiently transfected with either the A₁R or the A₃R. CHO-K1 are an established cell line frequently used to assay the activity of adenosine receptors.^{41,42} Both the A₁R and the A₃R couple to the inhibitory G protein family (G α_i) thereby reducing the cellular concentration of cAMP.

Using CHO-A₁R cells (CHO-K1 cells expressing the A₁R) we first confirmed that NECA, adenosine and CCPA were able to inhibit forskolin-stimulated cAMP production (Figure 5A) generating pIC₅₀ values (Table 3) equivalent to those previously reported.^{41,42} Further, all compounds (**5**, **6**, **7**, **16**, **17**, **18**, **20** and **21**) identified in the yeast as eliciting a functional A₁R response displayed full agonist activity against the A₁R in the mammalian cells, but with varying potencies (Figure 5B, Table 3). Significantly, when these compounds were assayed against the CHO-A₃R cells (Figure 5C and 5D, Table 3) only **7**, **17**, **20** and **21** were able to inhibit forskolin-stimulated cAMP production. Thus, taken together these data suggest that, at concentrations $\leq 1\mu\text{M}$, **5**, **6**, **16** and **18** display A₁R-selectivity. Intriguingly, 2-adamantyl derivative **18** is almost as potent an agonist of A₁R as NECA but completely A₁R-selective.

Table 3. Potency (pIC₅₀) and response range of reference ligands and putative A₁R selective compounds at the A₁R and A₃R as measured in transfected CHO-K1 cells.

Compd	A ₁ R			A ₃ R		
	pIC ₅₀ ^a	Response	n	pIC ₅₀ ^a	Response	n
		Range ^b			Range ^b	
NECA	9.68±0.16	-73.4±5.8	6	9.31±0.17	-44.1±3.0	8
Adenosine	8.63±0.11*	-66.4±3.7	6	8.94±0.14	-38.7±2.4	5
CCPA	9.30±0.15	-71.4±4.3	6	7.95±0.13**	-46.6±4.8	8
5	7.72±0.20**	-61.0±6.1	5	N.R	N.R	8
6	9.17±0.15	-55.28±3.6	4	N.R.	N.R.	6
7	8.36±0.17*	-60.0±4.4*	6	7.56±0.11**	-35.1±2.2	5
16	8.54±0.3*	-52.15±6.0*	6	N.R	N.R.	6
17	7.43±0.19	-39.3±3.9**	4	7.1±0.12**	-32.7±2.2*	6
18	9.40±0.34	-51.07±7.9	6	N.R	N.R	6
20	10.53±0.28*	-48.35±5.6*	4	6.57±0.15***	-38.0±4.0	5
21	8.21±0.2*	-47.67±4.3*	4	8.64±0.08	-37.9±1.2	5

Data are the mean ± SEM of *n* individual sets.

^aThe negative logarithm of the agonist concentration required to produce a half-maximal response.

^bThe response range of the agonists expressed as a percentage of total forskolin range (0-100%).

Statistical significance compared to NECA (*, *p* < 0.05, ** *p* < 0.01, *** *p* < 0.001) was determined by one-way ANOVA with Dunnett's post-test.

Figure 5. Determining the A₁R-selectivity of compounds isolated in the yeast screen against the A₁R and A₃R expressed in mammalian cells. CHO-K1 cells transiently transfected with A₁R (A, C and E) or A₃R (B, D and F) were stimulated with (●) NECA, (○) adenosine, (■) CCPA (A and B) or the compounds determined to be active at the A₁R from the yeast screen (▲) 7, (◇) 17, (■) 20, (△) 21 (C and D) (▼) 5,

(□) **6**, (▽) **16**, (●) **18** (E and F). In panels (C-F) NECA dose-inhibition curve is shown as grey dashed line with grey symbols. All cells were assayed for inhibition of 10 μ M forskolin-stimulated cAMP. Data are expressed as the percentage of the maximum response achieved when cells were stimulated with 10 μ M forskolin. Data are mean of 4-8 independent repeats $\pm$ SEM.

Molecular simulation of agonist docking into the A₁R

Based on the pharmacological experimental findings that most of our *N*⁶-substituted 5'-*N*-ethylcarboxamido and 5'-hydroxymethyl derivatives activated the A₁R, but all the 5'-(2-fluoro)thiophenyl derivatives failed to do so, we used a molecular modeling approach to dock all our synthetic adenosine derivatives into a homology model of the human A₁R. The recently solved crystal structure of the human A_{2A}R complexed with the agonist UK-432097 (PDB ID: 3QAK)⁴³ served as the template for this homology model. We reasoned that the bound agonist UK-432097 has a large *N*⁶-substituent (Figure 6A) as is the case for our synthetic adenosine analogues.

In order to validate the utility of this A_{2A}R crystal structure as a template for generating the A₁R homology model we docked compounds **20**, **21** and **34**, that also showed activity at the A_{2A}R in our assays, into the A_{2A}R crystal structure. Indeed, the proposed positions and side chain interactions for these compounds (Figure 6C and Supplementary Figure S3A and S3B) are very similar to known agonists bound to the A_{2A}R (Figure 6A and 6B).

Furthermore, after closely inspecting the crystal structures of the adenosine-, NECA- (Figure 6B) and UK-432097-bound (Figure 6A) human A_{2A}R (PDB IDs: 2YDO, 2YDV and 3QAK, respectively)^{43,44} we would argue that hydrogen bond formation between the ligand and the homologous Thr-91^{3,36}, Asn-254^{6,55}, Thr-277^{7,42} and His-278^{7,43} (superscript: Ballesteros-Weinstein numbering⁴⁵) in the A₁R is important to stabilize the active conformation of the receptor.^{43,44} These residues are highly conserved across the AR family. Taking this into consideration (details see *Experimental Section*) the docking yielded ligand

orientations for **5-7**, **16-18**, **20** and **21** (Figure 6D and Supplementary Figure S3C-I) that closely resemble the orientations of UK-432097- and NECA-bound to the human A_{2A}R (Figure 6A and 6B). In this distinct position the ribose moiety binds deeply into the binding pocket potentially forming hydrogen bonds with Thr-91^{3,36}, Asn-184^{5,42}, Thr-277^{7,42} and His-278^{7,43}. The purine ring π -stacks against Phe-171^{ECL2} and can form hydrogen bonds with Asn-254^{6,55}, whereas the bulky N⁶-substitutes are located near the exit of the binding pocket. We found experimentally that all these compounds were agonists at the A₁R in our yeast-based functional assay. Intriguingly, **6** and **20** were docked before they were tested, and based on our model, predicted to be active agonists, which indeed was the case.

The predicted binding positions for granatane derivatives **9** and **19** are somewhat similar, however, the purine ring is further away from Asn-254^{6,55} so that no hydrogen bonds are suggested (Figure 6E and Supplementary Figure S3J). At very high concentration, **9** and **19** were able to partially activate the A₁R, but it was experimentally not possible to obtain full dose response curves.

Docking of both inactive compounds **24** and **34** yielded binding positions where the purine ring adopts a *syn*-conformation with respect to the ribose (Figure 6F and Supplementary Figure S3K). It is also noticeable that **24** is not in close contact with Trp-247^{6,48}, a residue which is highly conserved across the AR family and in a recent molecular dynamics simulation was shown to act as a conformational toggle switch in the receptor activation mechanism.⁴⁶ The docking simulations with adenosine derivatives **25**, **35-37**, all of which failed to activate the A₁R, did not return any binding positions for our model.

Figure 6. Docking of N^6 -substituted adenosine derivatives into an A_1R homology model. (A) Crystal structures of human $A_{2A}R$ bound with agonist UK-432097 (gold, PDB ID: 3QAK) and (B) with agonist NECA (yellow, PDB ID: 2YDV) for comparison, indication key binding residues and interactions. Representative examples of proposed binding poses of N^6 -substituted adenosine derivatives in the $A_{2A}R$ crystal structure and in the A_1R homology model. (C) **21** (orange) docked into $A_{2A}R$ crystal structure. (D) **16** (light green), (E) **9** (light blue) and (F) **24** (pink) docked into A_1R homology model. Black dotted lines represent potential hydrogen bonds. Numbering of residues in (A-C) according to P29274 ($hA_{2A}R$) and of homologous residues in (D-F) according to P30542 (hA_1R). Ballesteros-Weinstein (BW) numbering: T88 (A_{2A}), T91 (A_1): BW 3.36; F168 (A_{2A}), F171 (A_1): BW ECL2; E169 (A_{2A}), E172 (A_1): BW ECL2; N181 (A_{2A}), N184 (A_1): BW 5.42; W246 (A_{2A}), W247 (A_1): BW 6.48; H250 (A_{2A}), H251 (A_1): BW 6.52; N253

(A_{2A}), N254 (A₁): BW 6.55; T270 (A₁): BW 7.35; Y271 (A_{2A}), Y271 (A₁): BW 7.36; S277 (A_{2A}), T277 (A₁): BW 7.42; H278 (A_{2A}), H278 (A₁): BW 7.43. For activities of docked compounds see Table 1. Proposed binding poses for the remaining compounds are shown in Figure S3 (*Supporting Information*).

Conclusions

Herein, we report the synthesis of a series of adenosine derivatives that were modified at the N⁶-position of the purine ring and the C-5' positions of the ribose moiety. These compounds were evaluated using a yeast-based and mammalian cell-based assay for quantifying their AR subtype selectivity. Our biological data show that compounds bearing a granatane azabicyclic moiety at N⁶ and/or a 5'-(2-fluorothiophenyl) substituent at the ribose fail to produce responses in A₁R, A_{2A}R or A_{2B}R cells. Conversely, N⁶-adamantyl adenosine and NECA congeners were completely A₁R selective. Moreover, it emerged that N⁶-(2-hydroxy)cyclopentyl and N⁶-(2-benzyloxy)cyclopentyl derivatives are potent agonists, preferentially activating A₁R over the other subtypes. It is worth noting that novel NECA derivative **20** exhibited higher potency and A₁R selectivity than its parent compound. Further, we present an A₁R homology model that corroborates our experimental findings. Notably, adenosine derivatives **5** and **6**, and novel NECA analogs **16** and **18** are completely A₁R-selective, potent agonists. Therefore they should represent useful tool compounds in purinergic signaling research and warrants further assessment of their therapeutic potential.

Experimental Section

General Chemistry. All reactions were performed under an inert argon atmosphere. Anhydrous tetrahydrofuran (THF), toluene and dichloromethane (DCM) were obtained by filtration through a system of alumina columns under a positive pressure of argon. Anhydrous dimethylformamide (DMF) was purchased as dry over molecular sieves from Sigma-Aldrich. Solvents were evaporated under reduced

pressure at approximately 45 °C using a Buchi Rotavapor or under high vacuum on a schlenk line. Reagents were purchased from Sigma-Aldrich, Acros, Alfa Aesar, Fischer Scientific or Hnseler and used without further purification. Reactions were monitored by thin layer chromatography (TLC) using aluminium sheets pre-coated with silica (Macherey-Nagel ALUGRAM Xtra SII, G/UV₂₅₄). Detection was under UV light source (λ_{max} 254 nm) or through staining with potassium permanganate solution (5%), vanillin spray or ninhydrin, with subsequent heating. Flash column chromatography was carried out using silica gel from Sigma-Aldrich (pore size 60 , 230–400 mesh particle size) as the stationary phase.

Proton nuclear magnetic resonance spectra (¹H NMR) were recorded using a Bruker Avance 300 or an Avance II 400 spectrometer. Chemical shifts (δ_{H}) are reported in parts per million (ppm) and are referenced to the residual solvent peak. The order of citation in parentheses is (1) number of equivalent nuclei (by integration), (2) multiplicity: s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), m (multiplet) *etc*), (3) coupling constants (*J*) in Hertz (Hz) and (4) assignment. Carbon nuclear magnetic resonance spectra (¹³C NMR) were recorded using a Bruker Avance 300 or an Avance II 400 spectrometer. Chemical shifts are quoted in parts per million (ppm) and are referenced to the residual solvent peak. The assignment is quoted in parentheses. COSY, HSQC and DEPT were routinely used to assign peaks in ¹H and ¹³C NMR spectra. Addition of D₂O was used to confirm the assignment of OH and NH peaks. Mass spectra and high resolution mass spectra (HRMS) were recorded on a ThermoScientific LTQ Orbitrap XL spectrometer consisting of a linear ion trap (LTQ) featuring a HCD collision cell, coupled to the Orbitrap mass analyzer, equipped with a nanoelectrospray ion source (NSI). MS and HRMS spectra were determined by the Mass Spectrometry Group at the Department of Chemistry and Biochemistry, University of Bern (PD Dr. S. Schurch).

The purity of the compounds was determined with UPLC-MS on a *Dionex* Ultimate 3000 using a reversed-phase column *Dionex* Acclaim RSLC, 120C18, 3 x 50 mm, 2.2 μm , 120  pore size, flow 1.2 mL/min. The gradient used was 100%A to 100%D over 7 min, with A (water with 0.1% TFA) and D (10%

H₂O/90% ACN+0.1% TFA). Purity was determined by total absorbance at 254 nm. All tested compounds were $\geq$ 95% pure, except **17** which was 94% pure.

Established Adenosine Agonists. 5'-N-ethylcarboxamidoadenosine (NECA), 2-chloro-N⁶-cyclopentyladenosine (CCPA), CGS-21680, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) and SLV-320 were purchased from R & D Systems (Bristol, UK). Where possible, compounds were prepared as 10mM stocks in DMSO.

Chemical Synthesis. Intermediates **2**,²⁹ **10**,³² **26**,³² and **27**³⁴ were synthesised as described in the literature with only slight experimental modifications. (3-*endo*)-9-Methyl-9-azabicyclo[3.3.1]nonan-3-amine was synthesised as described previously by our group.³⁰ *tert*-Butyl-9-azabicyclo[3.3.1]nonan-3-ylcarbamate (**22**) was synthesised as described previously.³³ Intermediate **29**⁴⁷ is known but was obtained with different methodology. Intermediate **28** is a novel compound. Further details on the synthesis and characterisation of these intermediates are available in the *Supporting Information*. 3-Amino-1-adamantanol and (1*R*,2*R*)-2-aminocyclopentanol hydrochloride were prepared as described in the *Supporting Information*.

General Procedure A for the Synthesis of Intermediates 3, 4, 8, 11–15, 23, 30–33. The appropriate chloride was dissolved in ethanol (20 mL/mmol). The amine and trimethylamine or DIPEA were then added and the reaction mixture was refluxed until TLC analysis indicated completion. The solvent was removed *in vacuo* and the resultant material was purified with column chromatography. The choice of base did not appear to have an effect on the yield or reaction time. In the case of compounds **4**, **8**, **13–15** and **31–33** the reaction was complete after 18 h, whereas sterically hindered **3**, **11**, **12**, **23** and **30** required 5 days refluxing at 120 °C to obtain sufficient amounts of product. In cases where the amine is a hydrochloride salt this was first stirred for 20 min with the base, before addition of the appropriate chloride in ethanol. For specific purification conditions see individual compounds.

General Procedure B for the Synthesis of Compounds 16–20, 24, 34–37. Acetonide protected compounds **11–15**, **23** or **30–33** were dissolved in water and acetic acid and stirred at 80 °C overnight. The water was removed *in vacuo* and the resultant crude material was purified with column chromatography.

General Procedure C for the Synthesis of Compounds 7 and 21. Benzyl protected compounds **4** and **20** were dissolved in ethanol (8 mL/mmol). Cyclohexene and Pd(OH)₂/C were added and refluxed at 100 °C until TLC indicated completion. The reaction mixture was allowed to cool to room temperature and filtered through celite. The crude material was purified with column chromatography.

General Procedure D for the Synthesis of Compounds 5, 6 and 9. Acetyl protected compounds **3**, **4** and **8** were dissolved in methanol (20 mL/mmol). Potassium carbonate was added and stirred vigorously for 3 h. The solvent was removed *in vacuo* and the crude material was purified with column chromatography.

6-*N*-(1-Adamantyl)-5'-*O*-acetyladenosine (3). **3** was synthesised according to the general procedure A, using chloride **2** (0.2 g, 0.48 mmol), amantadine hydrochloride (0.14 g, 0.72 mmol) and DIPEA (0.84 mL, 4.80 mmol). After purification with column chromatography (methanol/DCM, 2–6%) monoacetylated **3** was obtained as a white solid as the major product (0.13 g, 62% yield). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.31 (1H, s, adenine H), 8.22 (1H, s, adenine H), 6.61 (1H, s, NH), 5.89 (1H, d, *J* 5.1, 1'-H), 5.56 (1H, d, *J* 5.7, 2'-OH), 5.37 (1H, d, *J* 5.4, 3'-OH), 4.67 (1H, dd, *J* 10.5, 5.2, 2'-H), 4.32 (1H, dd, *J* 11.8, 3.7, 5'-HH), 4.26 (1H, dd, *J* 10.5, 5.4, 3'-H), 4.16 (1H, dd, *J* 11.8, 6.1, 5'-HH), 4.07 (1H, m, 4'-H), 2.21 (6H, m, 6 x adamantyl H), 2.08 (3H, m, 3 x adamantyl H), 2.00 (3H, s, CH₃), 1.68 (6H, m, 6 x adamantyl H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 170.1, 154.4, 151.9, 148.4, 139.5, 119.9, 87.9, 81.5, 72.8, 70.3, 63.9, 52.1, 41.0, 36.0, 29.0, 20.6; HRMS (ESI⁺) *m/z* calcd for C₂₂H₃₀N₅O₅ [MH]⁺ 444.2241, found 444.2229; purity UPLC-MS 99%, retention time = 2.92 min.

6-*N*-((1*R*,2*R*)-2-(Benzyloxy)cyclopentyl)-5'-*O*-acetyladenosine (4). **4** was synthesised according to the general procedure A, using chloride **2** (0.20 g, 0.48 mmol), (1*R*,2*R*)-1-amino-2-

benzyloxycyclopentane (0.13 mL, 0.72 mmol) and triethylamine (0.19 mL, 1.34 mmol). After purification with column chromatography (methanol/DCM, 1–4%) monoacetylated product **4** was obtained as a pale yellow solid as the major product (0.12 g, 52% yield). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.34 (1H, s, adenine H), 8.25 (1H, br s, adenine H), 7.90 (1H, m, NH), 7.33–7.18 (5H, m, 5 x phenyl H), 5.93 (1H, d, *J* 5.1, 1'-H), 5.57 (1H, d, *J* 5.7, 2'-OH), 5.37 (1H, d, *J* 5.3, 3'-OH), 4.68 (1H, dd, *J* 10.4, 5.1, 2'-H), 4.63–4.51 (3H, m, CH₂Ph and 1-H), 4.33 (1H, dd, *J* 11.8, 3.6, 5'-HH), 4.27 (1H, dd, *J* 10.4, 5.3, 3'-H), 4.18 (1H, dd, *J* 11.8, 6.2, 5'-HH), 4.09 (1H, m, 4'-H), 4.01 (1H, m, 2-H), 2.13–1.90 (5H, m, 2 x cyclopentyl H and CH₃), 1.80–1.55 (4H, m, 4 x cyclopentyl H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 170.1, 154.2, 152.5, 139.4, 138.9, 128.1, 127.3, 127.1, 114.5, 87.8, 84.1, 81.5, 72.9, 70.3, 70.1, 63.9, 56.4, 30.2, 21.4, 20.6; HRMS (ESI) calcd for C₂₄H₃₀O₅N₆ [MH]⁺ 484.2191, found 484.2172; purity UPLC-MS 99%, retention time = 2.55 min.

6-*N*-(1-Adamantyl)adenosine (5).⁴⁸ **5** was synthesised according to the general procedure D, using **3** (0.03 g, 0.06 mmol) and potassium carbonate (0.005 g, 0.04 mmol). After purification with column chromatography (methanol/DCM, 4%) product **5** was obtained as a white solid (0.03 g, 99% yield). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.35 (1H, s, adenine H), 8.21 (1H, s, adenine H), 6.65 (1H, s, NH), 5.87 (1H, d, *J* 6.1, 1'-H), 5.44 (1H, d, *J* 6.1, 2'-OH), 5.37 (1H, dd, *J* 7.1, 4.6, 5'-OH), 5.19 (1H, d, *J* 4.6, 3'-OH), 4.62 (1H, dd, *J* 11.1, 6.1, 2'-H), 4.15 (1H, m, 3'-H), 3.97 (1H, m, 4'-H), 3.69 (1H, m, 5'-HH), 3.55 (1H, m, 5'-HH), 2.23 (6H, m, 6 x adamantyl H), 2.10 (3H, m, 3 x adamantyl H), 1.69 (6H, m, 6 x adamantyl H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 154.5, 151.6, 148.2, 139.6, 120.1, 88.0, 85.8, 73.4, 70.6, 61.6, 52.2, 41.0, 36.0, 29.0; HRMS (ESI⁺) *m/z* calcd for C₂₀H₂₈N₅O₄ [MH]⁺ 402.2136, found 402.2137; purity UPLC 99%, retention time = 2.66 min.

6-*N*-((1*R*,2*R*)-2-(Benzyloxy)cyclopentyl)adenosine (6).⁴⁹ **6** was synthesised according to the general procedure D, using **4** (0.01 g, 0.02 mmol) and potassium carbonate (0.01 g, 0.07 mmol). After purification with column chromatography (methanol/DCM, 2–3%) product **6** was obtained as a white solid (0.01 g, 99% yield). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.37 (1H, s, adenine H), 8.24 (1H, br s, adenine H), 7.94 (1H, m, NH), 7.33–7.19 (5H, m, 5 x phenyl H), 5.89 (1H, d, *J* 6.1, 1'-H), 5.46–5.37 (2H, m, 2'-OH and

5'-OH), 5.19 (1H, d, J 4.6, 3'-OH), 4.68-4.50 (4H, m, 1-H, 2'-H and CH_2Ph), 4.15 (1H, dd, J 7.8, 4.6, 3'-H), 4.05-3.94 (2H, m, 2-H and 4'-H), 3.68 (1H, dt, J 12.0, 4.1, 5'-HH), 3.56 (1H, m, 5'-HH), 2.14-1.89 (2H, m, 2 x cyclopentyl H), 1.77-1.56 (4H, m, 4 x cyclopentyl H); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 154.2, 152.2, 139.6, 138.9, 128.1, 127.3, 127.1, 87.9, 85.8, 84.1, 73.5, 70.6, 70.1, 61.6, 30.1, 21.4; HRMS (ESI) calcd for $\text{C}_{22}\text{H}_{28}\text{O}_5\text{N}_5$ $[\text{MH}]^+$ 442.2085, found 442.2097; purity UPLC-MS 98%, retention time = 2.30 min.

6-*N*-((1*R*,2*R*)-2-(Hydroxy)cyclopentyl)adenosine (7).²⁸ **7** was synthesised according to the general procedure C, using **4** (0.03 g, 0.06 mmol), cyclohexene (0.25 mL, 2.43 mmol) and $\text{Pd}(\text{OH})_2/\text{C}$ (20 wt. %, 0.01 g). After purification with column chromatography (methanol/DCM, 2–8%) product **7** was obtained as a white solid (0.02 g, 95% yield). Minor quantities of the monoacetylated product were also isolated. ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 8.37 (1H, s, adenine H), 8.20 (1H, br s, adenine H), 7.74 (1H, d, J 6.8, NH), 5.89 (1H, d, J 6.1, 1'-H), 5.48-5.36 (2H, m, 2'-OH and 5'-OH), 5.19 (1H, d, J 4.6, 3'-OH), 4.87 (1H, m, 2-OH), 4.62 (1H, app. dd, J 11.3, 6.1, 2'-H), 4.29 (1H, br s, 1-H), 4.15 (1H, m, 3'-H), 4.06 (1H, m, 2-H), 3.97 (1H, m, 4'-H), 3.68 (1H, dt, J 11.9, 3.9, 5'-HH), 3.55 (1H, m, 5'-HH), 2.07 (1H, m, 1 x cyclopentyl H), 1.88 (1H, m, 1 x cyclopentyl H), 1.74-1.59 (2H, m, 2 x cyclopentyl H), 1.59-1.45 (2H, m, 2 x cyclopentyl H); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 154.7, 152.2, 139.6, 87.9, 85.9, 76.0, 73.5, 70.6, 61.6, 58.8, 32.3; HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{22}\text{O}_5\text{N}_5$ $[\text{MH}]^+$ 352.1615, found 352.1616; purity UPLC-MS 99%, retention time = 1.46 min.

Tri-*O*-acetyl-6-*N*-[(3-*endo*)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]adenosine (8). **8** was synthesised according to the general procedure A, using chloride **2** (0.3 g, 0.73 mmol), (3-*endo*)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine (0.45 g, 2.91 mmol) and DIPEA (0.15 mL, 0.88 mmol). After purification with column chromatography (methanol/DCM, 5–10%) product **8** was obtained as a white solid (0.21 g, 54% yield). ^1H NMR (400 MHz, $\text{MeOD}-d_4$) δ 8.30 (1H, br s, adenine H), 8.25 (1H, s, adenine H), 6.24 (1H, d, J 5.3, 1'-H), 6.03 (1H, t, J 5.3, 2'-H), 5.73 (1H, dd, J 5.3, 4.8, 3'-H), 4.83 (1H, br s, 3-H), 4.49-4.37 (3H, m, 4'-H and 5'-H₂), 3.44-3.42 (2H, m, 1- and 5-H), 2.77 (3H, s, NCH_3), 2.70-2.61 (2H, m, 2 x granatyl H), 2.20-2.03 (12H, m, 3 x CH_3 and 3 x granatyl H), 1.77-1.61 (3H, m, 3 x granatyl H), 1.43-1.40

(2H, m, 2 x granatyl H); ^{13}C NMR (100 MHz, $\text{MeOD-}d_4$) δ 172.2, 171.4, 171.2, 155.6, 154.3, 140.9, 87.9, 81.6, 74.3, 72.0, 64.2, 54.0, 41.7, 40.0, 32.6, 25.7, 20.6, 20.4, 20.2, 14.0; HRMS (ESI^+) m/z calcd for $\text{C}_{25}\text{H}_{35}\text{N}_6\text{O}_7$ 531.2562 $[\text{MH}]^+$, found 531.2553; purity UPLC-MS 96%, retention time = 2.14 min.

6-*N*-(3-*endo*)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]adenosine (9). **9** was synthesised according to the general procedure D, using **8** (0.05 g, 0.10 mmol) and potassium carbonate (0.005 g, 0.03 mmol). The crude product was dissolved in acetone and passed through filtered paper to give **9** as a white solid (0.04 g, 99% yield). ^1H NMR (300 MHz, $\text{MeOH-}d_4$) δ 8.24 (1H, s, adenine H), 8.21 (1H, br s, adenine H), 5.95 (1H, d, J 6.5, 1'-H), 4.77 (1H, br s overlapping, 3-H), 4.74 (1H, dd, J 6.4, 5.2, 2'-H), 4.32 (1H, dd, J 5.1, 2.5, 3'-H), 4.17 (1H, app q, J 2.4, 4'-H), 3.89 (1H, dd, J 12.6, 2.4, 5'-HH), 3.74 (1H, dd, J 12.6, 2.6, 5'-HH), 3.13-3.10 (2H, m, 1- and 5-H), 2.60-2.50 (5H, m, NCH_3 and 2 x granatyl H), 2.16-1.98 (3H, m, 3 x granatyl H), 1.58-1.45 (3H, m, 3 x granatyl H), 1.16-1.12 (2H, m, 2 x granatyl H); ^{13}C NMR (100 MHz, $\text{MeOH-}d_4$) δ 153.7, 141.4, 128.5, 91.4, 88.3, 75.5, 72.7, 63.6, 52.7, 42.7, 40.8, 33.4, 25.8, 15.0; HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{29}\text{O}_4\text{N}_6$ $[\text{MH}]^+$ 405.2245, found 405.2243; purity UPLC-MS 99%, retention time = 1.41 min.

6-*N*-(1-Adamantyl)-5'-ethylamino-2',3'-*O*-isopropylidene-5'-oxo-5'-deoxyadenosine (11). **11** was synthesised according to the general procedure A, using chloride **10** (0.3 g, 0.82 mmol), amantadine hydrochloride (0.46 g, 2.45 mmol) and DIPEA (2.61 mL, 15.01 mmol). After purification with column chromatography (methanol/DCM, 2%) product **11** was obtained as a white solid (0.28 g, 72% yield). ^1H NMR (300 MHz, $\text{DMSO-}d_6$) δ 8.27 (1H, s, adenine H), 8.17 (1H, s, adenine H), 7.51 (1H, t, J 5.6, amide NH), 6.62 (1H, s, amine NH), 6.34 (1H, d, J 1.5, 1'-H), 5.41 (1H, dd, J 6.1, 1.5, 2'-H), 5.38 (1H, dd, J 6.1, 1.8, 3'-H), 4.53 (1H, d, J 1.8, 4'-H), 2.80 (2H, m, CH_2CH_3), 2.21 (6H, m, 6 x adamantyl H), 2.09 (3H, m, 3 x adamantyl H), 1.68 (6H, m, 6 x adamantyl H), 1.54 (3H, s, CH_3), 1.35 (3H, s, CH_3), 0.62 (3H, t, J 7.2, CH_2CH_3); ^{13}C NMR (100 MHz, $\text{DMSO-}d_6$) δ 168.1, 154.4, 151.8, 148.0, 139.9, 119.6, 112.9, 89.5, 85.8, 83.2, 83.0, 52.1, 41.0, 36.0, 33.0, 29.0, 26.7, 25.0, 13.8; HRMS (ESI^+) m/z calcd for $\text{C}_{25}\text{H}_{35}\text{N}_6\text{O}_4$ $[\text{MH}]^+$ 483.2714, found 483.2718.

6-*N*-(3-Hydroxy-1-adamantyl)-5'-ethylamino-2',3'-*O*-isopropylidene-5'-oxo-5'-deoxyadenosine (12). **12** was synthesised according to the general procedure A, using chloride **10** (0.07 g, 0.19 mmol), 3-amino-1-adamantanol (0.05 g, 0.29 mmol) and triethylamine (0.5 mL, 3.6 mmol). After purification with column chromatography (methanol/DCM, 2–5%) product **12** was obtained as a white solid (0.07 g, 78% yield). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.26 (1H, s, adenine H), 8.16 (1H, s, adenine H), 7.49 (1H, t, *J* 5.6, amide NH), 6.74 (1H, s, amine NH), 6.33 (1H, d, *J* 1.1, 1'-H), 5.43-5.35 (2H, m, 2'-H and 3'-H), 4.53 (2H, s, 4'-H and OH), 2.81 (2H, m, CH₂CH₃), 2.18-2.01 (8H, m, 8 x adamantyl H), 1.65-1.43 (9H, m, 6 x adamantyl H and CH₃), 1.34 (3H, s, CH₃), 0.62 (3H, t, *J* 7.2, CH₂CH₃); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 168.1, 154.3, 151.7, 148.1, 140.0, 119.6, 112.9, 89.5, 85.6, 83.2, 83.0, 67.5, 54.6, 48.9, 44.2, 34.9, 33.0, 30.1, 26.7, 25.0, 13.8; HRMS (ESI⁺) *m/z* calcd for C₂₅H₃₅N₆O₅ 499.2663 [MH]⁺, found 499.2650; purity UPLC-MS 99%, retention time = 2.62 min.

6-*N*-(2-Adamantyl)-5'-ethylamino-2',3'-*O*-isopropylidene-5'-oxo-5'-deoxyadenosine (13). **13** was synthesised according to the general procedure A, using chloride **10** (0.02 g, 0.06 mmol), 2-adamantylamine hydrochloride (0.03 g, 0.18 mmol) and DIPEA (0.05 mL, 0.27 mmol). After purification with column chromatography (methanol/DCM, 2%) product **13** was obtained as a white solid (0.02 g, 69% yield). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.29 (1H, s, adenine H), 8.17 (1H, br s, adenine H), 7.48 (1H, t, *J* 5.7, amide NH), 7.05 (1H, br s, NH), 6.34 (1H, s, 1'-H), 5.45-5.36 (2H, m, 2'- and 3'-H), 4.53 (1H, s, 4'-H), 4.36 (1H, br s, adamantyl H), 2.80 (2H, m, CH₂CH₃), 2.11-2.05 (4H, m, 4 x adamantyl H), 1.84 (6H, m, 6 x adamantyl H), 1.72 (2H, m, 2 x adamantyl H), 1.53-1.50 (5H, m, 2 x adamantyl H and CH₃), 1.34 (3H, s, CH₃), 0.59 (3H, t, *J* 7.2, CH₂CH₃); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 168.1, 154.1, 152.3, 140.3, 112.9, 89.5, 85.9, 83.2, 83.1, 37.1, 36.9, 36.8, 33.0, 30.9, 26.7, 26.6, 25.0, 13.8; HRMS (ESI) calculated for C₂₅H₃₅N₆O₄ [MH]⁺ 483.2714, found 483.2707; purity UPLC-MS 94%, retention time = 3.12 min.

6-*N*-[(3-*endo*)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]-5'-ethylamino-2',3'-*O*-isopropylidene-5'-oxo-5'-deoxyadenosine (14). **14** was synthesised according to the general procedure A, using chloride **10** (0.1 g, 0.27 mmol), (3-*endo*)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine (0.17 g, 1.09 mmol) and

DIPEA (0.06 mL, 0.33 mmol). After purification with column chromatography (methanol/DCM, 5–10%) product **14** was obtained as a white solid (0.11 g, 85% yield). ¹H NMR (300 MHz, MeOD-*d*₄) δ 8.21 (2H, m, 2 x adenine H), 6.35 (1H, d, *J* 1.0, 1'-H), 5.63 (1H, dd, *J* 6.1, 1.8, 3'-H), 5.51 (1H, m, 2'-H), 4.77 (1H, br s, 3-H), 4.64 (1H, d, *J* 1.7, 4'-H), 3.27-3.23 (1H, m, 1- and 5-H), 2.85 (2H, m, CH₂CH₃), 2.67-2.50 (5H, m, NCH₃ and 2 x granatyl H), 2.20-2.00 (3H, m, 3 x granatyl H), 1.65-1.51 (6H, m, CH₃ and 3 x granatyl H), 1.42 (3H, s, CH₃) 1.34-1.19 (2H, m, 2 x granatyl H), 0.63 (3H, t, *J* 7.3, CH₂CH₃); ¹³C NMR (75 MHz, CDCl₃) 171.6, 155.6, 154.1, 142.0, 114.9, 92.4, 88.7, 85.3, 85.2, 53.3, 42.2, 40.4, 34.7, 33.1, 27.1, 25.8, 25.3, 14.6, 14.0; HRMS calculated for C₂₄H₃₆O₄N₇ [MH]⁺ 486.2823, found 486.2810; purity UPLC-MS 99%, retention time = 1.97 min.

6-*N*-((1*R*,2*R*)-2-(Benzyloxy)cyclopentyl)-5'-ethylamino-2',3'-*O*-isopropylidene-5'-oxo-5'-deoxyadenosine (15). **15** was synthesised according to the general procedure A, using chloride **10** (0.2 g, 0.54 mmol), (1*R*,2*R*)-1-amino-2-benzyloxycyclopentane (0.15 mL, 0.82 mmol) and triethylamine (0.21 mL, 1.51 mmol). Following removal of the solvent from the reaction mixture, the residue was dissolved in ethyl acetate (100 mL) and washed with water (2 x 50 mL). The organic phase was then dried over anhydrous Na₂SO₄ and the solvent was removed *in vacuo*. After purification with column chromatography (methanol/DCM, 1–3%) product **15** was obtained as a pale yellow solid (0.22 g, 79% yield). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.27 (1H, s, adenine H), 8.20 (1H, br s, adenine H), 7.91 (1H, m, amine NH), 7.51 (1H, t, *J* 5.7, amide NH), 7.33-7.20 (5H, m, 5 x phenyl H), 6.34 (1H, s, 1'-H), 5.43-5.36 (2H, m, 2'- and 3'-H), 4.66-4.49 (4H, m, 4'-H, CH₂Ph and 1-H), 4.01 (1H, m, 2-H), 2.81 (2H, m, CH₂CH₃), 2.12-1.89 (2H, m, 2 x cyclopentyl H), 1.80-1.56 (4H, m, 4 x cyclopentyl H), 1.54 (3H, s, CH₃), 1.34 (3H, s, CH₃), 0.61 (3H, t, *J* 7.2, CH₂CH₃); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 168.1, 154.1, 152.4, 148.2, 139.9, 138.9, 128.1, 127.3, 127.1, 112.9, 89.5, 85.8, 84.0, 83.2, 83.1, 70.1, 56.4, 33.0, 30.2, 26.7, 25.0, 21.3, 13.8; HRMS (ESI) calculated for C₂₇H₃₅O₅N₆ [MH]⁺ 523.2663, found 523.2649; purity UPLC-MS 99%, retention time = 3.08 min.

6-*N*-(1-Adamantyl)-5'-ethylamino-5'-oxo-5'-deoxyadenosine (16). **16** was synthesised according to the general procedure B, using **11** (0.10 g, 0.21 mmol), acetic acid (10 mL) and water (3 mL). After purification with column chromatography (methanol/DCM, 2–6%) product **16** was obtained as a white solid (0.09 g, 96% yield). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.89 (1H, t, *J* 5.5, amide NH), 8.39 (1H, s, adenine H), 8.27 (1H, s, adenine H), 6.77 (1H, s, amine NH), 5.95 (1H, d, *J* 7.7, 1'-H), 5.75 (1H, d, *J* 3.8, 3'-OH), 5.56 (1H, d, *J* 6.2, 2'-OH), 4.61 (1H, m, 2'-H), 4.30 (1H, d, *J* 1.2, 4'-H), 4.14 (1H, m, 3'-H), 3.22 (2H, m, CH₂CH₃), 2.23 (6H, m, 6 x adamantyl H), 2.09 (3H, m, 3 x adamantyl H), 1.68 (6H, m, 6 x adamantyl H), 1.08 (3H, t, *J* 7.2, CH₂CH₃); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 169.1, 154.6, 151.6, 148.0, 140.4, 120.4, 87.9, 84.7, 73.1, 71.9, 52.2, 41.0, 36.0, 33.2, 29.0, 14.7; IR [cm⁻¹] 3218, 2905, 2847, 1644; HRMS (ESI⁺) *m/z* calcd for C₂₂H₃₁N₆O₄ [MH]⁺ 443.2401, found 443.2393; purity UPLC 99%, retention time = 3.06 min.

6-*N*-(3-Hydroxy-1-adamantyl)-5'-ethylamino-5'-oxo-5'-deoxyadenosine (17). **17** was synthesised according to the general procedure B, using **12** (0.01 g, 0.02 mmol), acetic acid (3.6 mL) and water (1.2 mL). After purification with column chromatography (methanol/DCM, 1–5%) product **17** was obtained as a white solid (0.007 g, 78% yield). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.88 (1H, t, *J* 5.5, amide NH), 8.40 (1H, s, adenine H), 8.27 (1H, s, adenine H), 6.89 (1H, s, amine NH), 5.95 (1H, d, *J* 7.6, 1'-H), 5.74 (1H, d, *J* 4.2, 3'-OH), 5.57 (1H, d, *J* 6.4, 2'-OH), 4.61 (1H, m, 2'-H), 4.55 (1H, s, adamantyl OH), 4.30 (1H, d, *J* 1.2, 4'-H), 4.14 (1H, m, 3'-H), 3.21 (2H, m, CH₂CH₃), 2.20-2.05 (8H, m, 8 x adamantyl H), 1.66-1.43 (6H, m, 6 x adamantyl H), 1.08 (3H, t, *J* 7.2, CH₂CH₃); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 169.1, 154.5, 151.6, 148.0, 140.4, 120.3, 87.8, 84.7, 73.1, 72.0, 67.5, 54.7, 48.8, 44.2, 34.9, 33.3, 30.1, 14.7; HRMS (ESI⁺) *m/z* calcd for C₂₂H₃₁N₆O₅ [MH]⁺ 459.2350, found 459.2346; purity UPLC 94%, retention time = 2.18 min.

6-*N*-(2-Adamantyl)-5'-ethylamino-5'-oxo-5'-deoxyadenosine (18). **18** was synthesised according to the general procedure B, using **13** (0.02 g, 0.04 mmol), acetic acid (1.6 mL) and water (0.4 mL). After purification with column chromatography (methanol/DCM, 3–10%) product **18** was obtained

as a white solid (0.02 g, 99% yield). ^1H NMR (300 MHz, DMSO- d_6) δ 8.86 (1H, m, amide NH), 8.43 (1H, s, adenine H), 8.27 (1H, s, adenine H), 7.15 (1H, br s, amine NH), 5.97 (1H, d, J 7.5, 1'-H), 5.74 (1H, d, J 4.3, 3'-OH), 5.54 (1H, d, J 6.4, 2'-OH), 4.62 (1H, m, 2'-H), 4.37 (1H, br s, adamantyl H), 4.30 (1H, d, J 1.4, 4'-H), 4.14 (1H, m, 3'-H), 3.21 (2H, m, CH_2CH_3), 2.13-2.08 (4H, m, 4 x adamantyl H), 1.85 (6H, m, 6 x adamantyl H), 1.73 (2H, m, 2 x adamantyl H), 1.56-1.52 (2H, m, 2 x adamantyl H), 1.08 (3H, t, J 7.2, CH_2CH_3); ^{13}C NMR (100 MHz, DMSO- d_6) δ 169.1, 154.3, 152.3, 140.6, 114.5, 87.8, 84.6, 73.1, 71.9, 37.2, 36.9, 33.3, 30.9, 26.8, 14.7; HRMS (ESI) calcd for $\text{C}_{22}\text{H}_{31}\text{N}_6\text{O}_4$ $[\text{MH}]^+$ 443.2401, found 443.2392; purity UPLC-MS 99%, retention time = 2.69 min.

6-*N*-[(3-*endo*)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]-5'-ethylamino-5'-oxo-5'-

deoxyadenosine (19). **19** was synthesised according to the general procedure B, using **14** (0.03 g, 0.06 mmol), acetic acid (4.8 mL) and water (1.2 mL). After purification with column chromatography (methanol/DCM, 5–10%, with an additional 1% aqueous ammonia) product **19** was obtained as a white solid (0.03 g, 99% yield). ^1H NMR (300 MHz, MeOD- d_4) δ 8.30 (1H, br s, adenine H), 8.27 (1H, s, adenine H), 6.01 (1H, d, J 7.7, 1'-H), 4.81 (1H partially behind solvent signal, m, 3-H), 4.75 (1H, dd, J 7.6, 4.8, 2'-H), 4.47 (1H, d, J 1.5, 4'-H), 4.31 (1H, dd, J 4.8, 1.4, 3'-H), 3.37 (2H, m, CH_2CH_3), 3.28 (2H partially behind solvent signal, m, 1- and 5-H), 2.69-2.56 (5H, m, NCH_3 and 2 x granatyl H), 2.21-2.04 (3H, m, 3 x granatyl H), 1.68-1.56 (3H, m, 3 x granatyl H), 1.30 (2H, m, 2 x granatyl H), 1.21 (3H, t, J 7.3, CH_2CH_3); ^{13}C NMR (100 MHz, MeOD- d_4) δ 172.1, 155.8, 153.9, 142.1, 90.5, 86.5, 75.0, 73.4, 53.5, 42.1, 40.2, 35.1, 33.0, 25.7, 15.0, 14.4; HRMS (ESI) calcd for $\text{C}_{21}\text{H}_{32}\text{N}_7\text{O}_4$ $[\text{MH}]^+$ 446.2510, found 446.2523; purity UPLC-MS 99%, retention time = 1.62 min.

6-*N*-((1*R*,2*R*)-2-(Benzyloxy)cyclopentyl)-5'-ethylamino-5'-oxo-5'-deoxyadenosine (20). **20**

was synthesised according to the general procedure B, using **15** (0.01 g, 0.02 mmol), acetic acid (1.6 mL) and water (0.4 mL). After purification with column chromatography (methanol/DCM, 2–4%) product **20** was obtained as a white solid (0.01 g, 99% yield). ^1H NMR (400 MHz, DMSO- d_6) δ 8.90 (1H, t, J 5.6, amide NH), 8.41 (1H, s, adenine H), 8.30 (1H, br s, adenine H), 8.03 (1H, m, amine NH), 7.33-7.20 (5H,

m, 5 x phenyl H), 5.98 (1H, d, *J* 7.6, 1'-H), 5.73 (1H, d, *J* 4.3, 3'-OH), 5.53 (1H, d, *J* 6.5, 2'-OH), 4.67-4.53 (4H, m, 2'-H, CH₂Ph and 1-H), 4.32 (1H, d, *J* 1.5, 4'-H), 4.15 (1H, m, 3'-H), 4.03 (1H, m, 2-H), 3.23 (2H, m, CH₂CH₃), 2.08 (1H, m, 1 x cyclopentyl H), 1.96 (1H, m, 1 x cyclopentyl H), 1.79-1.60 (4H, m, 4 x cyclopentyl H), 1.09 (3H, t, *J* 7.2, CH₂CH₃); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 169.1, 154.3, 152.3, 140.4, 138.9, 128.1, 127.3, 127.1, 120.1, 87.8, 84.7, 84.1, 73.1, 72.0, 70.1, 56.4, 33.2, 30.2, 21.4, 14.7; HRMS (ESI) calcd for C₂₄H₃₁O₅N₆ [MH]⁺ 483.2350, found 483.2339; purity UPLC-MS 98%, retention time = 2.59 min.

6-*N*-((1*R*,2*R*)-2-(Hydroxy)cyclopentyl)-5'-ethylamino-5'-oxo-5'-deoxyadenosine (21). **21** was synthesised according to the general procedure C, using **20** (0.08 g, 0.17 mmol), cyclohexene (0.66 mL, 6.55 mmol) and Pd(OH)₂/C (20 wt. %, 0.02 g). After purification with column chromatography (methanol/DCM, 2–8%) product **21** was obtained as a white solid (0.07 g, 99% yield). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.91 (1H, t, *J* 5.4 Hz, amide NH), 8.41 (1H, s, adenine H), 8.26 (1H, br s, adenine H), 7.84 (1H, m, amine NH), 5.97 (1H, d, *J* 7.6, 1'-H), 5.75 (1H, d, *J* 4.3, 3'-OH), 5.55 (1H, d, *J* 6.5, 2'-OH), 4.86 (1H, m, 2-OH), 4.62 (1H, m, 2'-H), 4.31 (2H, m, 1-H and 4'-H), 4.14 (1H, m, 3'-H), 4.06 (1H, m, 2-H), 3.23 (2H, m, CH₂CH₃), 2.10 (1H, m, 1 x cyclopentyl H), 1.90 (1H, m, 1 x cyclopentyl H), 1.74-1.42 (4H, m, 4 x cyclopentyl H), 1.09 (3H, t, *J* 7.2, CH₂CH₃); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 169.1, 154.8, 152.2, 140.3, 87.8, 84.6, 76.0, 73.1, 72.0, 58.8, 33.3, 32.3, 20.4, 14.7; HRMS (ESI) calcd for C₁₇H₂₅O₅N₆ [MH]⁺ 393.1881, found 393.1873; purity UPLC-MS 99%, retention time = 2.21 min.

6-*N*-[(3-*endo*)-3-*tert*-Butyloxycarbonylamino-9-azabicyclo[3.3.1]non-3-yl]-5'-ethylamino-2',3'-*O*-isopropylidene-5'-oxo-5'-deoxyadenosine (23). **23** was synthesised according to the general procedure A, using chloride **10** (0.03 g, 0.08 mmol), *tert*-butyl-9-azabicyclo[3.3.1]nonan-3-ylcarbamate (**22**) (0.04 g, 0.16 mmol) and triethylamine (0.41 mL, 2.94 mmol). Following removal of the solvent from the reaction mixture, the residue was dissolved in ethyl acetate (100 mL) and washed with water (2 x 50 mL). The organic phase was then dried over anhydrous Na₂SO₄ and the solvent was removed *in vacuo*. After purification with column chromatography (methanol/DCM, 1–2%) product **23** was obtained as a pale

yellow solid (0.03 g, 67% yield). ^1H NMR (300 MHz, $\text{MeOD-}d_4$) δ 8.18 (1H, s, adenine H), 8.13 (1H, m, adenine H), 6.33 (1H, s, 1'-H), 6.16 (1H, m, 1- or 5-H), 5.61 (1H, m, 2'-H), 5.49 (1H, m, 3'-H), 5.42 (1H, m, 1- or 5-H), 4.62 (1H, d, J 1.7, 4'-H), 3.29 (1H, m, granatyl H), 2.85 (2H, m, CH_2CH_3), 2.42-2.16 (3H, m, 3 x granatyl H), 1.79-1.34 (22H, m, 2 x CH_3 , $-\text{C}(\text{CH}_3)_3$ and 7 x granatyl H), 0.66 (3H, dt, J 14.7, 7.2, CH_2CH_3); ^{13}C NMR (75 MHz, CDCl_3) 171.8, 155.4, 153.7, 140.6, 117.1, 115.0, 93.0, 88.9, 85.5, 85.3, 45.1, 44.1, 35.0, 33.6, 33.2, 32.5, 31.8, 30.9, 28.9, 27.2, 25.5, 15.0, 14.3; HRMS calculated for $\text{C}_{28}\text{H}_{42}\text{O}_6\text{N}_7$ $[\text{MH}]^+$ 572.3191, found 572.3187.

6-*N*-[(3-*endo*)-3-Amino-9-azabicyclo[3.3.1]non-3-yl]-5'-ethylamino-5'-oxo-5'-

deoxyadenosine (24). **24** was synthesised according to the general procedure B, using **23** (0.02 g, 0.03 mmol), acetic acid (1.5 mL) and water (0.5 mL). The crude product was purified by prep-LC, with an eluent gradient of 100% A to 60% D in 40 minutes. The fractions were collected and dried by lyophilization and product **24** was obtained as a white solid as the TFA salt (0.03 g, 99% yield). ^1H NMR (400 MHz, $\text{MeOD-}d_4$) δ 8.34 (1H, s, adenine H), 8.28 (1H, s, adenine H), 6.35 (1H, br s, 1- or 5-H), 6.03 (1H, d, J 7.6, 1'-H), 5.59 (1H, br s, 1- or 5-H), 4.74 (1H, dd, J 7.5, 4.8, 2'-H), 4.48 (1H, d, J 1.6, 4'-H), 4.30 (1H, dd, J 4.8, 1.5, 3'-H), 3.36 (2H, q, J 7.3, CH_2CH_3), 3.00 (1H, ddd, J 18.3, 12.2, 5.8, 3-H), 2.57 (2H, m, 2 x granatyl H), 2.18 (1H, m, 1 x granatyl H), 1.87-1.64 (7H, m, 7 x granatyl H), 1.20 (3H, t, J 7.3, CH_2CH_3); ^{13}C NMR (100 MHz, $\text{MeOD-}d_4$) δ 172.2, 155.2, 152.6, 150.7, 141.1, 121.8, 90.6, 86.4, 75.0, 73.5, 45.1, 35.1, 31.0, 15.0, 14.7; ^{19}F NMR (376 MHz, $\text{DMSO-}d_6$) δ -77.3; HRMS (ESI) calcd for $\text{C}_{20}\text{H}_{30}\text{O}_4\text{N}_7$ $[\text{MH}]^+$ 432.2354, found 432.2343; purity UPLC-MS 99%, retention time = 1.80 min.

6-*N*-[(3-*endo*)-3-Aminodimethyl-9-azabicyclo[3.3.1]non-3-yl]-5'-ethylamino-5'-oxo-5'-

deoxyadenosine (25). Formic acid (0.02 mL) and formaldehyde (37% aq. solution, 0.04 mL) were added to **24** (0.01 g, 0.02 mmol) and stirred at 90 °C overnight. Additional formic acid (0.02 mL) and formaldehyde (37% aq. solution, 0.04 mL) were added and stirred at 105 °C for 3 h. The reaction mixture was allowed to cool to room temperature and made alkaline with 1M NaOH solution. This was then thoroughly extracted with ethyl acetate (3 x 100 mL) and the combined organic extracts were washed with

sat. aq. NaHCO₃ (50 mL), water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄ and the solvent removed *in vacuo* to give **25** as white solid (0.006 g, 67% yield). ¹H NMR (300 MHz, MeOH-*d*₄) δ 8.27 (1H, s, adenine H), 8.21 (1H, s, adenine H), 6.26 (1H, br s, 1- or 5-H), 6.01 (1H, d, *J* 7.6, 1'-H), 5.49 (1H, br s, 1- or 5-H), 4.78 (1H, dd, *J* 7.7, 4.8, 2'-H), 4.46 (1H, d, *J* 1.4, 4'-H), 4.30 (1H, dd, *J* 4.8, 1.4, 3'-H), 3.38 (2H, m, CH₂CH₃), 2.45 (9H, m, 2 x CH₃ and 3 x granatyl H), 2.18 (1H, m, 1 x granatyl H), 1.77-1.58 (7H, m, 7 x granatyl H), 1.20 (3H, t, *J* 7.3, CH₂CH₃); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 172.1, 155.1, 153.3, 151.5, 140.8, 121.6, 90.4, 86.4, 75.0, 73.2, 58.6, 41.8, 35.1, 30.8, 15.1, 14.9; HRMS (ESI) calcd for C₂₂H₃₄O₄N₇ [MH]⁺ 460.2667, found 460.2661; purity UPLC-MS 99%, retention time = 1.87 min.

6-*N*-(1-Adamantyl)-5'-(2-fluorophenylthio)-2',3'-*O*-isopropylidene-5'-deoxyadenosine (30).

30 was synthesised according to the general procedure A, using chloride **29** (0.1 g, 0.23 mmol), amantadine hydrochloride (0.13 g, 0.69 mmol) and DIPEA (0.18 mL, 1.03 mmol). After purification with column chromatography (methanol/DCM, 0.5%) product **30** was obtained as a white solid (0.09 g, 69% yield). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.29 (1H, s, adenine H), 8.23 (1H, s, adenine H), 7.38 (1H, td, *J* 7.8, 1.6, Ar H), 7.31-7.07 (3H, m, 3 x Ar H), 6.67 (1H, s, amine NH), 6.17 (1H, d, *J* 2.2, 1'-H), 5.51 (1H, dd, *J* 6.2, 2.2, 2'-H), 5.05 (1H, dd, *J* 6.2, 2.7, 3'-H), 4.20 (1H, td, *J* 6.9, 2.5, 4'-H), 3.25 (2H overlapping with solvent signal, m, 5'-H₂), 2.22 (6H, m, 6 x adamantyl H), 2.09 (3H, m, 3 x adamantyl H), 1.75-1.63 (6H, m, 6 x adamantyl H), 1.49 (3H, s, CH₃), 1.31 (3H, s, CH₃); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 161.3, 158.9, 154.4, 151.9, 147.7, 139.8, 131.1, 128.5 (d, *J* 7.9), 124.9 (d, *J* 3.6), 121.8 (d, *J* 17.1), 119.9, 115.6 (d, *J* 21.9), 113.2, 89.5, 85.1, 83.4, 83.2, 52.2, 41.0, 36.0, 34.4, 29.0, 26.8, 25.1; ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -110.4; HRMS (ESI⁺) *m/z* calcd for C₂₉H₃₅N₅O₃FS [MH]⁺ 552.2439, found 552.2425.

6-*N*-[(3-*endo*)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]-5'-(2-fluorophenylthio)-2',3'-*O*-isopropylidene-5'-deoxyadenosine (31). **31** was synthesised according to the general procedure A, using chloride **29** (0.1 g, 0.23 mmol), (3-*endo*)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine (0.14 g, 0.92 mmol) and DIPEA (0.04 mL, 0.28 mmol). After purification with column chromatography (methanol/DCM, 5–10%) product **31** was obtained as a pale yellow solid (0.08 g, 61% yield). ¹H NMR (400 MHz, CDCl₃) δ

8.33 (1H, s, adenine H), 7.76 (1H, s, adenine H), 7.36 (1H, m, Ar H), 7.20 (1H, m, Ar H), 7.04-6.97 (2H, m, 2 x Ar H), 6.01 (1H, d, J 2.0, 1'-H), 5.54 (1H, dd, J 6.3, 1.9, 2'-H), 5.52 (1H overlapping with 2'-H signal, br s, NH), 5.10 (1H, dd, J 6.3, 2.8, 3'-H), 4.75 (1H, br s, 3-H), 4.37 (1H, td, J 7.2, 2.8, 4'-H), 3.25 (H, dd, J 13.7, 7.6, 5-HH), 3.17 (1H, dd, J 13.7, 6.5, 5-HH), 3.11 (2H, m, 1- and 5-H), 2.65-2.52 (2H, m, 2 x granatyl H), 2.50 (3H, s, NCH₃), 2.04-1.91 (3H, m, 3 x granatyl H), 1.56 (3H, s, CH₃), 1.53 (1H, m, granatyl H), 1.37 (3H, s, CH₃), 1.35-1.29 (2H, m, 2 x granatyl H), 1.02 (2H, m, 2 x granatyl H); ¹³C NMR (75 MHz, CDCl₃) 163.5, 160.2, 154.6, 153.5, 139.3, 133.3, 129.2 (d, J 8.0), 124.5 (d, J 3.8), 122.0 (d, J 17.5), 115.9 (d, J 22.5), 114.3, 91.3, 86.6, 84.2, 84.1, 51.4, 40.3, 36.2, 33.6, 27.1, 25.4, 24.2, 14.4; ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -108.4; HRMS calculated for C₂₈H₃₆O₃N₆FS [MH]⁺ 555.2548, found 555.2548; purity UPLC-MS 93%, retention time = 2.88 min.

6-*N*-((1*R*,2*R*)-2-(Benzyloxy)cyclopentyl)-5'-(2-fluorophenylthio)-2',3'-*O*-isopropylidene-5'-deoxyadenosine (32). **32** was synthesised according to the general procedure A, using chloride **29** (0.05 g, 0.11 mmol), (1*R*,2*R*)-1-amino-2-benzyloxycyclopentane (0.03 mL, 0.17 mmol) and triethylamine (0.04 mL, 0.31 mmol). After purification with column chromatography (methanol/DCM, 2%) product **32** was obtained as a sticky yellow oil (0.06 g, 99% yield). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.32 (1H, s, adenine H), 8.26 (1H, br s, adenine H), 7.96 (1H, m, amine NH), 7.39 (1H, td, J 7.8, 1.6, Ar H), 7.32-7.06 (8H, m, 8 x Ar H), 6.19 (1H, d, J 2.1, 1'-H), 5.51 (1H, dd, J 6.2, 2.1, 2'-H), 5.07 (1H, dd, J 6.2, 2.6, 3'-H), 4.67-4.47 (3H, m, 1-H and CH₂Ph), 4.21 (1H, td, J 7.1, 2.6, 4'-H), 4.01 (1H, m, 2-H), 3.25 (2H overlapping with solvent signal, m, 5'-H₂), 2.13-1.89 (2H, m, 2 x cyclopentyl H), 1.79-1.57 (4H, m, 4 x cyclopentyl H), 1.49 (3H, s, CH₃), 1.31 (3H, s, CH₃); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 161.3, 158.9, 154.2, 152.5, 147.9, 139.8, 138.9, 131.1, 128.5 (d, J 7.9), 128.1, 127.3, 127.1, 124.9 (d, J 3.5), 121.8 (d, J 17.1), 115.6 (d, J 22.0), 113.2, 89.4, 85.2, 84.0, 83.4, 83.2, 70.1, 56.5, 34.4, 30.1, 26.8, 25.1, 21.4; ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -110.4; HRMS (ESI) calculated for C₃₁H₃₅O₄N₅FS [MH]⁺ 592.2388, found 592.2378; purity UPLC-MS 94%, retention time = 3.98 min.

6-*N*-((1*R*,2*R*)-2-(Hydroxy)cyclopentyl)-5'-(2-fluorophenylthio)-2',3'-*O*-isopropylidene-5'-deoxyadenosine (33). **33** was synthesised according to the general procedure A using chloride **29** (0.05 g, 0.11 mmol), (1*R*,2*R*)-2-aminocyclopentanol hydrochloride (0.02 g, 0.14 mmol) and triethylamine (0.04 mL, 0.31 mmol). After purification with column chromatography (methanol/DCM, 2%) product **33** was obtained as a white solid (0.04 g, 73% yield). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.31 (1H, s, adenine H), 8.22 (1H, br s, adenine H), 7.76 (1H, m, NH), 7.39 (1H, td, *J* 7.8, 1.6, Ar H), 7.31-7.07 (3H, m, 3 x Ar H), 6.18 (1H, d, *J* 2.1, 1'-H), 5.51 (1H, dd, *J* 6.2, 2.1, 2'-H), 5.06 (1H, dd, *J* 6.2, 2.7, 3'-H), 4.86 (1H, m, 2-OH), 4.27 (1H, br s, 1-H), 4.21 (1H, td, *J* 7.1, 2.6, 4'-H), 4.06 (1H, m, 2-H), 3.26 (2H overlapping with solvent signal, m, 5'-H₂), 2.06 (1H, m, 1 x cyclopentyl H), 1.89 (1H, m, 1 x cyclopentyl H), 1.72-1.60 (2H, m, 2 x cyclopentyl H), 1.60-1.43 (5H, m, 2 x cyclopentyl H and CH₃), 1.32 (3H, s, CH₃); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 161.3, 158.9, 154.7, 152.5, 139.8, 131.1, 128.6 (d, *J* 7.9), 124.9 (d, *J* 3.5), 121.8 (d, *J* 17.1), 115.6 (d, *J* 22.0), 113.2, 89.5, 85.1, 83.4, 83.2, 76.0, 58.9, 34.4, 32.3, 26.8, 25.1, 20.4; ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -110.4; HRMS (ESI) calculated for C₂₄H₂₉O₄N₅FS [MH]⁺ 502.1919, found 502.1912; purity UPLC-MS 99%, retention time = 3.14 min.

6-*N*-(1-Adamantyl)-5'-(2-fluorophenylthio)-5'-deoxyadenosine (34). **34** was synthesised according to the general procedure B, using **30** (0.01 g, 0.02 mmol), acetic acid (3.2 mL) and water (0.8 mL). After purification with column chromatography (methanol/DCM, 1–3%) product **34** was obtained as a white solid (0.004 g, 40% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.32 (1H, s, adenine H), 8.21 (1H, s, adenine H), 7.46 (1H, td, *J* 7.8, 1.6, Ar H), 7.29-7.12 (3H, m, 3 x Ar H), 6.60 (1H, s, NH), 5.87 (1H, d, *J* 5.7, 1'-H), 5.51 (1H, d, *J* 6.1, 2'-OH), 5.37 (1H, d, *J* 5.0, 3'-OH), 4.82 (1H, dd, *J* 11.1, 5.7, 2'-H), 4.22 (1H, dd, *J* 8.7, 4.9, 3'-H), 4.00 (1H, m, 4'-H), 3.42 (1H, dd, *J* 13.8, 5.5, 5'-HH), 3.31 (1H overlapping with solvent signal, m, 5'-HH), 2.23 (6H, m, 6 x adamantyl H), 2.10 (3H, m, 3 x adamantyl H), 1.68 (6H, m, 6 x adamantyl H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 161.1, 158.7, 154.4, 151.9, 148.5, 139.7, 130.5, 128.1 (d, *J* 7.9), 125.0 (d, *J* 3.4), 122.6 (d, *J* 17.1), 119.9, 115.5 (d, *J* 21.8), 87.7, 82.8, 72.7, 72.5, 52.1, 41.0, 36.0,

34.6, 29.0; ^{19}F NMR (376 MHz, $\text{DMSO-}d_6$) δ -110.78; HRMS (ESI^+) m/z calcd for $\text{C}_{26}\text{H}_{31}\text{N}_5\text{O}_3\text{FS}$ $[\text{MH}]^+$ 512.2126, found 512.2130.

6-*N*-[(3-*endo*)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]-5'-(2-fluorophenylthio)-5'-deoxyadenosine (35). **35** was synthesised according to the general procedure B, using **31** (0.01 g, 0.02 mmol), acetic acid (3.2 mL) and water (0.8 mL). After purification with column chromatography (methanol/DCM, 1–10%, with an additional 1% aqueous ammonia) product **35** was obtained as a white solid (0.005 g, 50% yield). ^1H NMR (400 MHz, $\text{MeOD-}d_4$) δ 8.24 (1H, s, adenine H), 8.17 (1H, s, adenine H), 7.45 (1H, m, Ar H), 7.21 (1H, m, Ar H), 7.07-7.01 (2H, m, 2 x Ar H), 5.95 (1H, d, J 5.2, 1'-H), 4.84 (1H, 2'-H under solvent signal as determined by COSY analysis), 4.83 (1H, br s, 3-H, partially hidden by solvent signal), 4.37 (1H, m, 3'-H), 4.20 (1H, m, 4'-H), 3.40 (2H, m, CH_2CH_3), 3.31 (2H, 1- and 5-H under solvent signal as determined by COSY analysis), 2.70-2.57 (5H, m, NCH_3 and 2 x granatyl H), 2.16-2.04 (3H, m, 3 x granatyl H), 1.69-1.59 (3H, m, 3 x granatyl H), 1.32-1.29 (2H, m, 2 x granatyl H); ^{13}C NMR (100 MHz, $\text{MeOD-}d_4$) δ 163.8, 155.6, 154.0, 140.9, 133.2, 129.7 (d, J 7.9), 125.7 (d, J 3.7), 116.5 (d, J 22.5), 90.1, 85.0, 74.7, 74.1, 53.7, 40.2, 36.5, 32.9, 25.7, 14.3, 7.6; ^{19}F NMR (376 MHz, $\text{DMSO-}d_6$) δ -111.5; HRMS (ESI^+) m/z calcd for $\text{C}_{25}\text{H}_{32}\text{N}_6\text{O}_3\text{FS}$ $[\text{MH}]^+$ 515.2235, found 515.2240; purity UPLC-MS 99%, retention time = 2.24 min.

6-*N*-((1*R*,2*R*)-2-(Benzyloxy)cyclopentyl)-5'-(2-fluorophenylthio)-5'-deoxyadenosine (36).⁴⁷ **36** was synthesised according to the general procedure B, using **32** (0.02 g, 0.03 mmol), acetic acid (3.2 mL) and water (0.8 mL). After purification with column chromatography (methanol/DCM, 1–3%) product **36** was obtained as a pale yellow solid (0.02 g, 99% yield). ^1H NMR (300 MHz, $\text{DMSO-}d_6$) δ 8.35 (1H, s, adenine H), 8.24 (1H, br s, adenine H), 7.89 (1H, m, amine NH), 7.46 (1H, m, Ar H), 7.33-7.10 (8H, m, 8 x Ar H), 5.90 (1H, d, J 5.6, 1'-H), 5.52 (1H, d, J 6.0, 2'-OH), 5.38 (1H, d, J 5.1, 3'-OH), 4.81 (1H, dd, J 11.1, 5.6, 2'-H), 4.68-4.50 (3H, m, 1-H and CH_2Ph), 4.21 (1H, dd, J 8.7, 4.8, 3'-H), 4.00-3.97 (2H, m, 4'-H and 2-H), 3.42 (1H, dd, J 13.8, 5.5, 5'-HH), 3.32 (1H overlapping with solvent signal, m, 5'-HH) 2.14-1.91 (2H, m, 2 x cyclopentyl H), 1.77-1.58 (4H, m, 4 x cyclopentyl H); ^{13}C NMR (100 MHz, $\text{DMSO-}d_6$) δ

161.1, 158.7, 154.2, 152.5, 139.6, 139.0, 130.5, 128.1, 128.0, 127.3, 127.1, 125.0 (d, J 3.4), 122.6 (d, J 17.2), 155.5 (d, J 21.9), 87.6, 84.1, 82.8, 72.7, 72.6, 70.1, 56.4, 34.6, 30.2, 21.4; ^{19}F NMR (376 MHz, DMSO- d_6) δ -110.8; HRMS (ESI) calcd for $\text{C}_{28}\text{H}_{31}\text{O}_4\text{N}_5\text{FS}$ $[\text{MH}]^+$ 552.2075, found 552.2071; purity UPLC-MS 99%, retention time = 3.14 min.

6-*N*-((1*R*,2*R*)-2-(Hydroxy)cyclopentyl)-5'-(2-fluorophenylthio)-5'-deoxyadenosine (37).¹⁴ **37** was synthesised according to the general procedure B, using **33** (0.01 g, 0.02 mmol), acetic acid (3.2 mL) and water (0.8 mL). After purification with column chromatography (methanol/DCM, 1–5%) product **37** was obtained as a white solid (0.005 g, 56% yield). The *O*-acetylated product was also isolated in small quantities. ^1H NMR (300 MHz, DMSO- d_6) δ 8.34 (1H, s, adenine H), 8.21 (1H, br s, adenine H), 7.69 (1H, d, J 7.1, amine NH), 7.47 (1H, td, J 7.8, 1.6, Ar H), 7.31-7.10 (3H, m, 3 x Ar H), 5.89 (1H, d, J 5.7, 1'-H), 5.54 (1H, d, J 6.0, 2'-OH), 5.40 (1H, d, J 5.0, 3'-OH), 4.87 (1H, d, J 4.0, 2-OH), 4.80 (1H, dd, J 10.9, 5.6, 2'-H), 4.30 (1H, br s, 1-H), 4.21 (1H, dd, J 8.6, 4.7, 3'-H), 4.09-3.95 (2H, m, 4'-H and 2-H), 3.42 (1H, dd, J 13.7, 5.5, 5'-HH), 3.32 (1H, m, 5'-HH), 2.07 (1H, m, 1 x cyclopentyl H), 1.90 (1H, m, 1 x cyclopentyl H), 1.72-1.42 (4H, m, 4 x cyclopentyl H); ^{13}C NMR (100 MHz, DMSO- d_6) δ 161.1, 158.7, 154.6, 152.4, 139.6, 130.5 (d, J 1.7), 128.1 (d, J 7.9), 125.0 (d, J 3.4), 122.6 (d, J 17.1), 115.5 (d, J 21.8), 87.6, 82.8, 76.1, 72.7, 72.6, 58.8, 34.6, 32.3, 20.4; ^{19}F NMR (376 MHz, DMSO- d_6) δ -110.8; HRMS (ESI) calcd for $\text{C}_{21}\text{H}_{25}\text{O}_4\text{N}_5\text{FS}$ $[\text{MH}]^+$ 462.1606, found 462.1590; purity UPLC-MS 95%, retention time = 2.35 min.

Biology Materials. Yeast extract and yeast nitrogen base were purchased from Difco (Franklin Lakes, NJ). All other reagents were purchased from Sigma-Aldrich (St. Louis, MO).

Constructs and DNA Manipulation. p426-GPD-A₁R was kindly provided by Professor Arthur Christopoulos and Dr. Lauren May (Monash University, Australia). Mammalian expression vectors containing the A₁R, A_{2A}R, A_{2B}R and A₃R were purchased from Missouri S&T cDNA Resource Center (<http://cdna.org>) (Rolla, MO). DNA manipulations were performed using standard techniques. Oligonucleotides were supplied by Invitrogen and PCR amplification performed using FastStart Taq

polymerase (Roche Diagnostics, Burgess Hill, UK). All constructs generated by PCR were sequenced by GATC (GATC Biotech, London, UK) prior to use.

General Yeast Methods. General yeast procedures were performed as described previously.¹⁶ Cells were routinely cultured in YPDA (yeast, peptone, dextrose and adenine). Yeast transformations were achieved using the lithium acetate/single-stranded DNA/polyethylene glycol method as previously described.⁵⁰ Cells were selected for uracil biosynthesis and routinely cultured in synthetic dropout media lacking uracil (SD-URA).

Yeast Strain Construction. The production of the dual reporter strains expressing chimeras of five C-terminal amino acids of human Gα protein with the yeast Gpa1p, 1-467 (GPA1/Gα) has been described previously.¹⁶ Mammalian GPCRs were introduced into the yeast strains (MMY12, MMY14, MMY19, MMY22, MMY23, MMY25 and MMY28) using the p426-GPD expression plasmid. Positive isolates were selected upon their ability to generate β-galactosidase activity above basal when stimulated with 100 μM NECA. For chimeric strains that did not initially appear to functionally couple ($n \geq 16$ isolates) to the ARs, expression and membrane localization were confirmed using fluorescence microscopy.

Yeast Reporter Gene Assay. Yeast cells were treated with compounds as described in Dowell and Brown.¹⁶ Initially cells were cultured overnight in SD-URA at 30°C. Cells were diluted 1:10 in SD-URA and allowed to grow for 8 hours at 30°C. Finally cell density was adjusted to an OD₆₀₀ of 0.02 and treated with 1% (v/v) of the appropriate compound dissolved in DMSO in a 96-well plate for 16 hours at 30°C. For compounds dissolved in other solvents the media was supplemented with 1% (v/v) DMSO prior to treatment. To compensate for an elevated basal signal, the A_{2A}R was routinely cultured in SD-URA lacking histidine (SD-URA-HIS) and treatment media supplemented with 5mM 3-amino-triazole. All strains used in this study contain the *lacZ* gene under the control of the pheromone-responsive *FUS1* promoter. To assess β-galactosidase activity cells were lysed as previously described.^{19,51-53} 2-Nitrophenyl β-D-galactopyranoside (ONPG) was used as a chromogenic substrate for β-galactosidase and detected by OD₄₃₀. Absorbance was measured using a Mithras LB940 microplate reader (Berthold Technologies, Harpenden, UK). The strains are Δ*far1* and are therefore incapable of cell cycle arrest induced by the pheromone-

response. Consequently, these cells grow throughout treatment. To compensate for variability in cell number and bleed through from the chromogenic reporter, cell density was measured by OD₆₂₀ and a response calculated as (OD₄₃₀-OD₆₂₀)/OD₆₂₀.

Confocal Microscopy of Yeast. To visual receptor expression C-terminal in-frame fusion constructs between the A₁R, A_{2A}R and A_{2B}R and GFP was generated using the two-step cloning method described by Ladds *et al.*⁵⁴ These receptors were expressed in yeast using p426-GPD vector consistent with their untagged counterparts. Isolates were cultured for 24 h in SD-URA. 100 µL cells were harvested by centrifugation, washed in PBS and briefly sonicated. Cells were imaged using a True Confocal Scanner Leica TCS SP5 microscope (Leica Microsystems Ltd., Milton Keynes, UK) and were processed using ImageJ as described previously.⁵⁵

Mammalian Cell Culture and Transfection. CHO-K1 cells, provided by Dr Ewan St. John Smith (University of Cambridge), were routinely cultured in Hams-F12, supplemented with 10% fetal bovine serum (FBS), and maintained at 37°C, in humidified air with 5% CO₂. Cells were transfected with 2 µg DNA using FuGene® 6 at a 3:1 (w:v) DNA:FuGene 6 ratio. Cells were harvested 48 h post transfection for assaying.

cAMP Accumulation Assay. Transfected cells were washed with PBS and resuspended in stimulation buffer (PBS containing 0.1% BSA and 25 µM rolipram). Cells were seeded at 2500 cells per well in 384-well white Optiplates. Cells were then simultaneously incubated with 10 µM forskolin (to stimulate cAMP production) and adenosine receptors ligands (ranging between 1 µM to 10 pM) for 30 min at room temperature. Cells were then lysed and the extent of cAMP accumulation measured using a LANCE® cAMP Detection Kit (PerkinElmer). Plates were read using a Mithras LB 940 multimode plate reader (Berthold Technologies).

Data Analysis. Data were analyzed using Prism 6.0e (Graphpad Software, San Diego, CA). Concentration response curves were fitted using the three-parameter logistic equation to obtain EC₅₀ and E_{max}. Schild analysis was performed in Prism as described by Motulsky and Christopoulos.⁵⁶ Non-linear regression of the operational model of pharmacological agonism³⁶ was used to obtain values for efficacy

($\log \tau$) and the equilibrium dissociation constant ($\log K_A$). These values were then used to quantify signaling bias as the change in $\log (\tau/K_A)$ relative to NECA.³⁷ We have used this method previously to enable quantification of G protein bias^{19,20} but here we have extended the analysis to include receptor selectivity. Since the receptors are expressed in the same cell background, and that NECA is a full potent agonist against all receptor subtypes, we reasoned that changes in $\log (\tau/K_A)$ for a given ligand, relative to NECA for each AR would provide a quantitative means of comparing receptor selectivity. Statistically significant differences were detected using one-way ANOVA with Bonferroni's or Dunnett's multiple comparison tests or Student T-tests as appropriate and a probability (p) < 0.05 was considered significant.

Homology Modeling and Docking. The protein sequence of the human A₁R (accession number P30542) was aligned with an agonist (UK-432097)-bound human A_{2A}R template (PDB ID: 3QAK) using PSI-Coffee⁵⁷ (Figure S4). MODELLER v9.14⁵⁸ was used to build 500 models and the best model selected according to the inbuilt molecular probability function. The ligands were constructed *ab initio* in Chem3D Pro v14.0 (PerkinElmer, Waltham, MA) and energy-minimised using the included MM2 force field. For each ligand a library of 200 conformers was generated using OMEGA v2.5 (OpenEye Scientific Software, Santa Fe, NM). FRED RECEPTOR v2.2.5 (OpenEye Scientific Software) was utilized to generate a docking template whereas the binding site was defined as a box of $V = 9486 \text{ \AA}^3$ around the bound UK-432097 agonist. For predicting the binding poses, the ligands were docked into this binding site template using FRED v2.1 (OpenEye Scientific Software) that utilizes an exhaustive process to position and score all conformers of a ligand at all possible positions within the defined binding site. Binding poses that did not form a hydrogen bond with either Thr-91^{3,36}, Asn-254^{6,55} or Thr-277^{7,42} were discarded (*hA₁R* numbering according to P30542, superscript: Ballesteros-Weinstein numbering⁴⁵). Ten docking poses were generated for each ligand, ranked using the inbuilt Chemgauss3 scoring function and visualized with PyMOL v1.7 (Schrödinger LLC, Portland, OR).

Supporting Information

Synthesis procedures and spectral data for synthetic intermediates, reproduction of ^1H and ^{13}C NMR spectra, purity assessment for final compounds, Schild analysis of compounds **36** and **37**, functional assessment of A₃R in yeast and predicted docking poses for compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Author information

Corresponding authors:

*M.L.: phone +41 31 631 3311; fax +41 31 631 4272; E-mail martin.lochner@dcb.unibe.ch

*G.L.: phone +44 1223 334020; fax +44 1223 334100; E-mail grl30@cam.ac.uk

Notes:

The authors declare no competing financial interest.

#A.K. and J.L.H. contributed equally to this work.

Acknowledgments

This study was supported by the Swiss National Science Foundation (SNSF professorship PP00P2_123536 and PP00P2_146321 to M.L.), the BBSRC (G.L., BB/G01227X/1 and BB/M00015X/1), an MRC Doctoral Training Partnership (I.W. MR/J003964/1), and the EPSRC (A.K., EP/G500045/1).

Abbreviations Used

AR, adenosine receptor; A₁R, A₁ adenosine receptor; A_{2A}R, A_{2A} adenosine receptor; A_{2B}R, A_{2B} adenosine receptor; A₃R, A₃ adenosine receptor; CCPA, 2-chloro-*N*⁶-cyclopentyladenosine; DIPEA, di-*iso*-propyl ethyl amine (Hünig's base); GAPDH, glyceraldehyde-3-phosphate dehydrogenase; Gpa1p, guanine nucleotide-binding protein alpha-1 subunit; NECA, 5'-*N*-ethylcarboxamidoadenosine.

References

- (1) Sachdeva, S.; Gupta, M. Adenosine and its receptors as therapeutic targets: an overview. *Saudi Pharm. J.* **2013**, *21*, 245-253.
- (2) Dale, N.; Frenguelli, B. G. Release of adenosine and ATP during ischemia and epilepsy. *Curr. Neuropharmacol.* **2009**, *7*, 160-179.
- (3) Fredholm, B. B.; Chen, J.-F.; Cunha, R. A.; Svenningsson, P.; Vaugeois, J.-M. Adenosine and brain function. *Int. Rev. Neurobiol.* **2005**, *63*, 191-270.
- (4) Chen, J.-F.; Sonsalla, P. K.; Pedata, F.; Melani, A.; Domenici, M. R.; Popoli, P.; Geiger, J.; Lopes, L. V.; de Mendonça, A. Adenosine A_{2A} receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and “fine tuning” modulation. *Progr. Neurobiol.* **2007**, *83*, 310-331.
- (5) Stewart, G. D.; Valant, C.; Dowell, S. J.; Mijaljica, D.; Devenish, R. J.; Scammells, P. J.; Sexton, P. M.; Christopoulos, A. Determination of adenosine A₁ receptor agonist and antagonist pharmacology using *Saccharomyces cerevisiae*: implications for ligand screening and functional selectivity. *J. Pharmacol. Exp. Ther.* **2009**, *331*, 277-286.
- (6) Nell, P. G.; Albrecht-Küpper, B. The adenosine A₁ receptor and its ligands. *Progr. Med. Chem.* **2009**, *47*, 163-201.
- (7) Petrelli, R.; Torquati, I.; Kachler, S.; Luongo, L.; Maione, S.; Franchetti, P.; Grifantini, M.; Novellino, E.; Lavecchia, A.; Klotz, K.-N.; Cappellacci, L. 5'-C-Ethyl-tetrazolyl-*N*⁶-substituted adenosine and 2-chloro-adenosine derivatives as highly potent dual acting A₁ adenosine receptor agonists and A₃ adenosine receptor antagonists. *J. Med. Chem.* **2015**, *58*, 2560-2566.
- (8) Franchetti, P.; Cappellacci, L.; Vita, P.; Petrelli, R.; Lavecchia, A.; Kachler, S.; Klotz, K.-N.; Marabese, I.; Luongo, L.; Maione, S.; Grifantini, M. *N*⁶-Cycloalkyl- and *N*⁶-bicycloalkyl-C5'(C2')-

modified adenosine derivatives as high-affinity and selective agonists at the human A₁ adenosine receptor with antinociceptive effects in mice. *J. Med. Chem.* **2009**, *52*, 2393-2406.

(9) Ashton, T. D.; Aumann, K. M.; Baker, S. P.; Schiesser, C. H.; Scammells, P. J. Structure–activity relationships of adenosines with heterocyclic *N*⁶-substituents. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 6779-6784.

(10) Hutchinson, S. A.; Baker, S. P.; Scammells, P. J. Adenosine receptor ligands with oxygenated *N*⁶-substituents. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 933-936.

(11) Cappellacci, L.; Franchetti, P.; Pasqualini, M.; Petrelli, R.; Vita, P.; Lavecchia, A.; Novellino, E.; Costa, B.; Martini, C.; Klotz, K.-N.; Grifantini, M. Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists. *J. Med. Chem.* **2005**, *48*, 1550-1562.

(12) Cappellacci, L.; Franchetti, P.; Vita, P.; Petrelli, R.; Lavecchia, A.; Costa, B.; Spinetti, F.; Martini, C.; Klotz, K.-N.; Grifantini, M. 5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A₁ adenosine receptor agonists: affinity, efficacy, and selectivity for A₁ receptor from different species. *Bioorg. Med. Chem.* **2008**, *16*, 336-353.

(13) Morrison, C. F.; Elzein, E.; Jiang, B.; Ibrahim, P. N.; Marquart, T.; Palle, V.; Shenk, K. D.; Varkhedkar, V.; Maa, T.; Wu, L.; Wu, Y.; Zeng, D.; Fong, I.; Lustig, D.; Leung, K.; Zablocki, J. A. Structure–affinity relationships of 5'-aromatic ethers and 5'-aromatic sulfides as partial A₁ adenosine agonists, potential supraventricular anti-arrhythmic agents. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 3793-3797.

(14) Fatholahi, M.; Xiang, Y.; Wu, Y.; Li, Y.; Wu, L.; Dhalla, A. K.; Belardinelli, L.; Shryock, J. C. A novel partial agonist of the A₁-adenosine receptor and evidence of receptor homogeneity in adipocytes. *J. Pharmacol. Exp. Ther.* **2006**, *317*, 676-684.

- (15) Brown, A. J.; Dyos, S. L.; Whiteway, M. S.; White, J. H. M.; Watson, M.-A. E. A.; Marzioch, M.; Clare, J. J.; Cousens, D. J.; Paddon, C.; Plumpton, C.; Romanos, M. A.; Dowell, S. J. Functional coupling of mammalian receptors to the yeast mating pathway using novel yeast/mammalian G protein α -subunit chimeras. *Yeast* **2000**, *16*, 11-22.
- (16) Dowell, S. J.; Brown, A. J. Yeast assays for G-protein-coupled receptors. *Receptors Channels* **2002**, *8*, 343-352.
- (17) Brown, A. J.; Goldsworthy, S. M.; Barnes, A. A.; Eilert, M. M.; Tcheang, L.; Daniels, D.; Muir, A. I.; Wigglesworth, M. J.; Kinghorn, I.; Fraser, N. J.; Pike, N. B.; Strum, J. C.; Steplewski, K. M.; Murdock, P. R.; Holder, J. C.; Marshall, F. H.; Szekeres, P. G.; Wilson, S.; Ignar, D. M.; Foord, S. M.; Wise, A.; Dowell, S. J. The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. *J. Biol. Chem.* **2003**, *278*, 11312-11319.
- (18) Bertheleme, N.; Singh, S.; Dowell, S. J.; Hubbard, J.; Byrne, B. Loss of constitutive activity is correlated with increased thermostability of the human adenosine A_{2A} receptor. *Br. J. Pharmacol.* **2013**, *169*, 988-998.
- (19) Weston, C.; Poyner, D.; Patel, V.; Dowell, S.; Ladds, G. Investigating G protein signalling bias at the glucagon-like peptide-1 receptor in yeast. *Br. J. Pharmacol.* **2014**, *171*, 3651-3665.
- (20) Weston, C.; Lu, J.; Li, N.; Barkan, K.; Richards, G. O.; Roberts, D. J.; Skerry, T. M.; Poyner, D.; Pardamwar, M.; Reynolds, C. A.; Dowell, S. J.; Willars, G. B.; Ladds, G. Modulation of glucagon receptor pharmacology by receptor activity-modifying protein-2 (RAMP2). *J. Biol. Chem.* **2015**, *290*, 23009-23022.
- (21) Peeters, M. C.; van Westen, G. J. P.; Guo, D.; Wisse, L. E.; Müller, C. E.; Beukers, M. W.; Ijzerman, A. P. GPCR structure and activation: an essential role for the first extracellular loop in activating the adenosine A_{2B} receptor. *FASEB J.* **2011**, *25*, 632-643.

- (22) Peeters, M. C.; Wisse, L. E.; Dinaj, A.; Vroling, B.; Vriend, G.; Ijzerman, A. P. The role of the second and third extracellular loops of the adenosine A₁ receptor in activation and allosteric modulation. *Biochem. Pharmacol.* **2012**, *84*, 76-87.
- (23) Liu, R.; Groenewoud, N. A.; Peeters, M.; Lenselink, E.; Ijzerman, A. A yeast screening method to decipher the interaction between the adenosine A_{2B} receptor and the C-terminus of different G protein α -subunits. *Purinergic Signal.* **2014**, *10*, 441-453.
- (24) Ladds, G.; Goddard, A.; Davey, J. Functional analysis of heterologous GPCR signalling pathways in yeast. *Trends Biotechnol.* **2005**, *23*, 367-373.
- (25) Brown, A. J.; Daniels, D. A.; Kassim, M.; Brown, S.; Haslam, C. P.; Terrell, V. R.; Brown, J.; Nichols, P. L.; Staton, P. C.; Wise, A.; Dowell, S. J. Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. *J. Pharmacol. Exp. Ther.* **2011**, *337*, 236-246.
- (26) Gao, Z.-G.; Blaustein, J. B.; Gross, A. S.; Melman, N.; Jacobson, K. A. N⁶-Substituted adenosine derivatives: selectivity, efficacy, and species differences at A₃ adenosine receptors. *Biochem. Pharmacol.* **2003**, *65*, 1675-1684.
- (27) Jagtap, P.; Andover, N. Adenosine compounds and their use thereof. WO2011/119919 A1, **2011**.
- (28) Knutsen, L. J. S.; Lau, J.; Petersen, H.; Thomsen, C.; Weis, J. U.; Shalmi, M.; Judge, M. E.; Hansen, A. J.; Sheardown, M. J. N-Substituted adenosines as novel neuroprotective A₁ agonists with diminished hypotensive effects. *J. Med. Chem.* **1999**, *42*, 3463-3477.
- (29) Kotra, L. P.; Manouilov, K. K.; Cretton-Scott, E.; Sommadossi, J.-P.; Boudinot, F. D.; Schinazi, R. F.; Chu, C. K. Synthesis, biotransformation, and pharmacokinetic studies of 9-(β -D-arabinofuranosyl)-6-azidopurine: a prodrug for ara-A designed to utilize the azide reduction pathway. *J. Med. Chem.* **1996**, *39*, 5202-5207.

- (30) Vernekar, S. K. V.; Hallaq, H. Y.; Clarkson, G.; Thompson, A. J.; Silvestri, L.; Lummis, S. C. R.; Lochner, M. Toward biophysical probes for the 5-HT₃ receptor: structure–activity relationship study of granisetron derivatives. *J. Med. Chem.* **2010**, *53*, 2324-2328.
- (31) Gao, Z.-G.; Mamedova, L. K.; Chen, P.; Jacobson, K. A. 2-Substituted adenosine derivatives: affinity and efficacy at four subtypes of human adenosine receptors. *Biochem. Pharmacol.* **2004**, *68*, 1985-1993.
- (32) Middleton, R. J.; Briddon, S. J.; Cordeaux, Y.; Yates, A. S.; Dale, C. L.; George, M. W.; Baker, J. G.; Hill, S. J.; Kellam, B. New fluorescent adenosine A₁-receptor agonists that allow quantification of ligand-receptor interactions in microdomains of single living cells. *J. Med. Chem.* **2007**, *50*, 782-793.
- (33) Yang, Z.; Manning, D. D. 2-Alkylbenzoxazole carboxamides as 5-HT₃ modulators. US2008/0214601 A1, **2008**.
- (34) Verheyden, J. P. H.; Moffatt, J. G. Halo sugar nucleosides. III. Reactions for the chlorination and bromination of nucleoside hydroxyl groups. *J. Org. Chem.* **1972**, *37*, 2289-2299.
- (35) Ijzerman, A. P.; Fredholm, B. B.; Jacobson, K. A.; Linden, J.; Müller, C. E. Adenosine receptors: A₁ receptor. Last modified on 23/07/2015. Accessed on 14/08/2015. IUPHAR/BPS Guide to PHARMACOLOGY, <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=18>.
- (36) Black, J. W.; Leff, P. Operational models of pharmacological agonism. *Proc. R. Soc. Lond. B. Biol. Sci.* **1983**, *220*, 141-162.
- (37) Figueroa, K. W.; Griffin, M. T.; Ehlert, F. J. Selectivity of agonists for the active state of M1 to M4 muscarinic receptor subtypes. *J. Pharmacol. Exp. Ther.* **2009**, *328*, 331-342.
- (38) Gurden, M. F.; Coates, J.; Ellis, F.; Evans, B.; Foster, M.; Hornby, E.; Kennedy, I.; Martin, D. P.; Strong, P.; Vardey, C. J.; Wheeldon, A. Functional characterization of three adenosine receptor types. *Br. J. Pharmacol.* **1993**, *109*, 693-698.

- (39) Colca, J. R. Discontinued drugs 2011: endocrine and metabolic. *Exp. Opin. Investig. Drugs* **2012**, *21*, 1619-1624.
- (40) Yang, M.; Chu, R.; Chisholm, J. W.; Doege, H.; Belardinelli, L.; Dhalla, A. K. Adenosine A₁ receptors do not play a major role in the regulation of lipogenic gene expression in hepatocytes. *Eur. J. Pharmacol.* **2012**, *683*, 332-339.
- (41) Cordeaux, Y.; Briddon, S. J.; Alexander, S. P. H.; Kellam, B.; Hill, S. J. Agonist-occupied A₃ adenosine receptors exist within heterogeneous complexes in membrane microdomains of individual living cells. *FASEB J.* **2008**, *22*, 850-860.
- (42) Baker, J. G.; Hill, S. J. A comparison of the antagonist affinities for the G_i- and G_s-coupled states of the human adenosine A₁-receptor. *J. Pharmacol. Exp. Ther.* **2007**, *320*, 218-228.
- (43) Xu, F.; Wu, H.; Katritch, V.; Han, G. W.; Jacobson, K. A.; Gao, Z.-G.; Cherezov, V.; Stevens, R. C. Structure of an agonist-bound human A_{2A} adenosine receptor. *Science* **2011**, *332*, 322-327.
- (44) Lebon, G.; Warne, T.; Edwards, P. C.; Bennett, K.; Langmead, C. J.; Leslie, A. G. W.; Tate, C. G. Agonist-bound adenosine A_{2A} receptor structures reveal common features of GPCR activation. *Nature* **2011**, *474*, 521-525.
- (45) Ballesteros, J. A.; Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. In *Methods in Neurosciences*; Stuart, C. S., Ed.; Academic Press: San Diego, 1995; Vol. 25, pp 366-428.
- (46) Yuan, S.; Hu, Z.; Filipek, S.; Vogel, H. W246^{6.48} opens a gate for a continuous intrinsic water pathway during activation of the adenosine A_{2A} receptor. *Angew. Chem. Int. Ed.* **2015**, *54*, 556-559.
- (47) Elfatih, E.; Prabha, I.; Venkata, P.; Vaibhav, V.; Zablocki, J. Partial and full agonists of A₁ adenosine receptors. US2005/0020532 A1, **2005**.

- (48) Hong, C. I.; Tritsch, G. L.; Mittelman, A.; Hebborn, P.; Chheda, G. B. Synthesis and antitumor activity of 5'-phosphates and cyclic 3',5'-phosphates derived from biologically active nucleosides. *J. Med. Chem.* **1975**, *18*, 465-473.
- (49) Zablocki, J.; Elfatih, E.; Organ, M.; Bilokin, Y.; Mayer, S.; Disanti, A.; Miller, S.; Kernast, P. Partial and full agonists of A₁ receptors. US2006/0052330 A1, **2006**.
- (50) Gietz, R. D.; Schiestl, R. H. Microtiter plate transformation using the LiAc/SS carrier DNA/PEG method. *Nat. Protocols* **2007**, *2*, 35-37.
- (51) Dohlman, H. G.; Apaniesk, D.; Chen, Y.; Song, J.; Nusskern, D. Inhibition of G-protein signaling by dominant gain-of-function mutations in Sst2p, a pheromone desensitization factor in *Saccharomyces cerevisiae*. *Mol. Cell. Biol.* **1995**, *15*, 3635-43.
- (52) Didmon, M.; Davis, K.; Watson, P.; Ladds, G.; Broad, P.; Davey, J. Identifying regulators of pheromone signalling in the fission yeast *Schizosaccharomyces pombe*. *Curr. Genet.* **2002**, *41*, 241-253.
- (53) Ladds, G.; Davis, K.; Hillhouse, E. W.; Davey, J. Modified yeast cells to investigate the coupling of G protein-coupled receptors to specific G proteins. *Mol. Microbiol.* **2003**, *47*, 781-792.
- (54) Ladds, G.; Davis, K.; Das, A.; Davey, J. A constitutively active GPCR retains its G protein specificity and the ability to form dimers. *Mol. Microbiol.* **2005**, *55*, 482-497.
- (55) Croft, W.; Hill, C.; McCann, E.; Bond, M.; Esparza-Franco, M.; Bennett, J.; Rand, D.; Davey, J.; Ladds, G. A physiologically required G protein-coupled receptor (GPCR)-regulator of G protein signaling (RGS) interaction that compartmentalizes RGS activity. *J. Biol. Chem.* **2013**, *288*, 27327-27342.
- (56) Motulsky, H. A.; Christopoulos, A. *Fitting models to biological data using linear and nonlinear regression: a practical guide to curve fitting*; Oxford University Press: New York, 2004.
- (57) Notredame, C.; Higgins, D. G.; Heringa, J. T-coffee: a novel method for fast and accurate multiple sequence alignment. *J. Mol. Biol.* **2000**, *302*, 205-217.

(58) Webb, B.; Sali, A. Comparative protein structure modeling using MODELLER. In *Current Protocols in Bioinformatics*; John Wiley & Sons, Inc.: 2002.

Table of Contents Graphic